ZA200408588B - Nucleoside derivatives for treating hepatitis C virus infection - Google Patents
Nucleoside derivatives for treating hepatitis C virus infection Download PDFInfo
- Publication number
- ZA200408588B ZA200408588B ZA200408588A ZA200408588A ZA200408588B ZA 200408588 B ZA200408588 B ZA 200408588B ZA 200408588 A ZA200408588 A ZA 200408588A ZA 200408588 A ZA200408588 A ZA 200408588A ZA 200408588 B ZA200408588 B ZA 200408588B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted
- ribofuranosyl
- methyl
- purine
- heteroaryl
- Prior art date
Links
- 150000003833 nucleoside derivatives Chemical class 0.000 title claims description 69
- 208000010710 hepatitis C virus infection Diseases 0.000 title description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 111
- 125000000623 heterocyclic group Chemical group 0.000 claims description 102
- 150000001875 compounds Chemical class 0.000 claims description 100
- 239000002777 nucleoside Substances 0.000 claims description 88
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 86
- -1 guanidino, amidino Chemical group 0.000 claims description 71
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- 229910052739 hydrogen Inorganic materials 0.000 claims description 59
- 239000001257 hydrogen Substances 0.000 claims description 58
- 235000000346 sugar Nutrition 0.000 claims description 50
- 125000003118 aryl group Chemical group 0.000 claims description 46
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 44
- 125000003107 substituted aryl group Chemical group 0.000 claims description 41
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 39
- 125000003342 alkenyl group Chemical group 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 36
- 125000000304 alkynyl group Chemical group 0.000 claims description 33
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 33
- 241000711549 Hepacivirus C Species 0.000 claims description 30
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 29
- 229930024421 Adenine Natural products 0.000 claims description 27
- 229960000643 adenine Drugs 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 22
- 238000010168 coupling process Methods 0.000 claims description 18
- 238000005859 coupling reaction Methods 0.000 claims description 17
- 125000002252 acyl group Chemical group 0.000 claims description 16
- 230000008878 coupling Effects 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000002342 ribonucleoside Substances 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- 150000002576 ketones Chemical class 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 8
- 125000004442 acylamino group Chemical group 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 239000001226 triphosphate Substances 0.000 claims description 6
- 235000011178 triphosphate Nutrition 0.000 claims description 6
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 239000001177 diphosphate Substances 0.000 claims description 5
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 5
- 235000011180 diphosphates Nutrition 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 150000004712 monophosphates Chemical class 0.000 claims description 5
- 125000002524 organometallic group Chemical group 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 125000005907 alkyl ester group Chemical group 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 239000012038 nucleophile Substances 0.000 claims description 4
- UHWJKAXFMGPTNB-UHFFFAOYSA-N 2-(3h-indol-3-yl)acetic acid Chemical compound C1=CC=C2C(CC(=O)O)C=NC2=C1 UHWJKAXFMGPTNB-UHFFFAOYSA-N 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 150000007860 aryl ester derivatives Chemical class 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- DDSCCYSKFCZQMP-UHFFFAOYSA-N purine-6-caboxamide Chemical compound NC(=O)C1=NC=NC2=C1N=CN2 DDSCCYSKFCZQMP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 description 106
- 230000015572 biosynthetic process Effects 0.000 description 100
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 67
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 33
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 33
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 30
- 125000003545 alkoxy group Chemical group 0.000 description 27
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 23
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 125000005843 halogen group Chemical group 0.000 description 22
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 21
- 125000004104 aryloxy group Chemical group 0.000 description 20
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 125000003835 nucleoside group Chemical group 0.000 description 19
- 125000001424 substituent group Chemical group 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 125000005415 substituted alkoxy group Chemical group 0.000 description 17
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 14
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 14
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 125000006239 protecting group Chemical group 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 150000003212 purines Chemical class 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 125000004001 thioalkyl group Chemical group 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 9
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 8
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 8
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 8
- 239000007800 oxidant agent Substances 0.000 description 8
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 8
- 150000003230 pyrimidines Chemical class 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 7
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 7
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 7
- 125000005012 alkyl thioether group Chemical group 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 7
- 229940104302 cytosine Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 229940035893 uracil Drugs 0.000 description 7
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 102000006992 Interferon-alpha Human genes 0.000 description 6
- 108010047761 Interferon-alpha Proteins 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000004423 acyloxy group Chemical group 0.000 description 6
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 6
- 229960000329 ribavirin Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 5
- PASOFFRBGIVJET-YRKGHMEHSA-N (2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 PASOFFRBGIVJET-YRKGHMEHSA-N 0.000 description 4
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 4
- 239000005751 Copper oxide Substances 0.000 description 4
- 229910004373 HOAc Inorganic materials 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 239000003810 Jones reagent Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 239000007868 Raney catalyst Substances 0.000 description 4
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000011609 ammonium molybdate Substances 0.000 description 4
- 229940010552 ammonium molybdate Drugs 0.000 description 4
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- JGDFBJMWFLXCLJ-UHFFFAOYSA-N copper chromite Chemical compound [Cu]=O.[Cu]=O.O=[Cr]O[Cr]=O JGDFBJMWFLXCLJ-UHFFFAOYSA-N 0.000 description 4
- 229910000431 copper oxide Inorganic materials 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 4
- DKWOHBPRFZIUQL-UHFFFAOYSA-N dimethyl-methylidene-oxo-$l^{6}-sulfane Chemical compound C[S+](C)([CH2-])=O DKWOHBPRFZIUQL-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 4
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 239000003444 phase transfer catalyst Substances 0.000 description 4
- 229960005235 piperonyl butoxide Drugs 0.000 description 4
- 239000012286 potassium permanganate Substances 0.000 description 4
- 239000002212 purine nucleoside Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 229910001927 ruthenium tetroxide Inorganic materials 0.000 description 4
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 4
- CRWJEUDFKNYSBX-UHFFFAOYSA-N sodium;hypobromite Chemical compound [Na+].Br[O-] CRWJEUDFKNYSBX-UHFFFAOYSA-N 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000005000 thioaryl group Chemical group 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 4
- DEFRJUSVKPUISM-GITKWUPZSA-N (2r,3r,4r,5r)-2-(6-amino-8-bromopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1Br DEFRJUSVKPUISM-GITKWUPZSA-N 0.000 description 3
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 3
- NDVMCQUOSYOQMZ-UHFFFAOYSA-N 2,2-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)C(C(N)=O)[Si](C)(C)C NDVMCQUOSYOQMZ-UHFFFAOYSA-N 0.000 description 3
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 3
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 229910019093 NaOCl Inorganic materials 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 125000005325 aryloxy aryl group Chemical group 0.000 description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical compound [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000006345 epimerization reaction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- LBQAJLBSGOBDQF-UHFFFAOYSA-N nitro azanylidynemethanesulfonate Chemical group [O-][N+](=O)OS(=O)(=O)C#N LBQAJLBSGOBDQF-UHFFFAOYSA-N 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 125000001979 organolithium group Chemical group 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 3
- 239000003586 protic polar solvent Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 2
- JMKGQDWDDNBXKB-UHFFFAOYSA-N 1,2,3,4-tetrahydrofuro[3,2-d]pyrimidine Chemical class N1CNCC2=C1C=CO2 JMKGQDWDDNBXKB-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- RXQZLSRIOOYKLF-UHFFFAOYSA-N 5H-pyrazolo[4,3-d]triazine Chemical compound N1=NN=C2C=NNC2=C1 RXQZLSRIOOYKLF-UHFFFAOYSA-N 0.000 description 2
- CTGFGRDVWBZYNB-UHFFFAOYSA-N 6-bromo-7h-purine Chemical compound BrC1=NC=NC2=C1NC=N2 CTGFGRDVWBZYNB-UHFFFAOYSA-N 0.000 description 2
- FBZSTISQQTUEFV-UHFFFAOYSA-N 6-cyclopentyl-1h-pyrimidin-2-one Chemical compound C1=CNC(=O)N=C1C1CCCC1 FBZSTISQQTUEFV-UHFFFAOYSA-N 0.000 description 2
- PXWUFPXFNHCNPY-UHFFFAOYSA-N 6-phenyl-7h-purin-2-amine Chemical compound C=12NC=NC2=NC(N)=NC=1C1=CC=CC=C1 PXWUFPXFNHCNPY-UHFFFAOYSA-N 0.000 description 2
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 2
- WDHAAJIGSXNPFO-UHFFFAOYSA-N 8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CN=C2NC(=O)C=CC2=C1 WDHAAJIGSXNPFO-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000006154 Chronic hepatitis C Diseases 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000016600 Inosine-5'-monophosphate dehydrogenases Human genes 0.000 description 2
- 108050006182 Inosine-5'-monophosphate dehydrogenases Proteins 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000006859 Swern oxidation reaction Methods 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000005620 boronic acid group Chemical class 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 239000005549 deoxyribonucleoside Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical class C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003195 pteridines Chemical class 0.000 description 2
- KLDGHPMEPAPPFX-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=CN=CC2=CC(C(=O)N)=CN=C21 KLDGHPMEPAPPFX-UHFFFAOYSA-N 0.000 description 2
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical class C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- IXDZFGATLNCIOI-NGJCXOISSA-N (3r,4r,5r)-3,4,5,6-tetrahydroxyhexan-2-one Chemical class CC(=O)[C@H](O)[C@H](O)[C@H](O)CO IXDZFGATLNCIOI-NGJCXOISSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- GZSFNZAVQZGNTG-UHFFFAOYSA-N 1,8-dihydropteridine-4,7-dione Chemical compound N1C(=O)C=NC2=C1NC=NC2=O GZSFNZAVQZGNTG-UHFFFAOYSA-N 0.000 description 1
- URLHRHRAFNNWCG-UHFFFAOYSA-N 1-(7H-purin-2-yl)pyrrolidine-2-carboxamide Chemical compound NC(=O)C1N(CCC1)C1=NC=C2NC=NC2=N1 URLHRHRAFNNWCG-UHFFFAOYSA-N 0.000 description 1
- GRLFHRFLBFFQBK-UHFFFAOYSA-N 1-ethyl-4-nitropyrrole-2-carboxylic acid Chemical compound CCN1C=C([N+]([O-])=O)C=C1C(O)=O GRLFHRFLBFFQBK-UHFFFAOYSA-N 0.000 description 1
- GEGNYFQOFWUIFG-UHFFFAOYSA-N 1-methyl-4-nitro-1h-pyrrole-2-carboxylic acid Chemical compound CN1C=C([N+]([O-])=O)C=C1C(O)=O GEGNYFQOFWUIFG-UHFFFAOYSA-N 0.000 description 1
- FADDGUDTESIUNX-UHFFFAOYSA-N 1-phenylpyrimidin-2-one Chemical compound O=C1N=CC=CN1C1=CC=CC=C1 FADDGUDTESIUNX-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- AXIMEEWBBDTVHN-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1C=CN2 AXIMEEWBBDTVHN-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 1
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- ZEZJPIDPVXJEME-UHFFFAOYSA-N 2,4-Dihydroxypyridine Chemical compound OC=1C=CNC(=O)C=1 ZEZJPIDPVXJEME-UHFFFAOYSA-N 0.000 description 1
- GFISDBXSWQMOND-UHFFFAOYSA-N 2,5-dimethoxyoxolane Chemical compound COC1CCC(OC)O1 GFISDBXSWQMOND-UHFFFAOYSA-N 0.000 description 1
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 1
- JYMKNRXYRVQXCV-UHFFFAOYSA-N 2-(1h-1,2,4-triazol-5-yl)pyrimidine Chemical compound N1C=NC(C=2N=CC=CN=2)=N1 JYMKNRXYRVQXCV-UHFFFAOYSA-N 0.000 description 1
- BZWBMICECYGNAZ-UHFFFAOYSA-N 2-(1h-pyrrol-3-yl)-7h-purine Chemical compound N1C=CC(C=2N=C3N=CNC3=CN=2)=C1 BZWBMICECYGNAZ-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- HBJGQJWNMZDFKL-UHFFFAOYSA-N 2-chloro-7h-purin-6-amine Chemical compound NC1=NC(Cl)=NC2=C1NC=N2 HBJGQJWNMZDFKL-UHFFFAOYSA-N 0.000 description 1
- JCAFIKMITONRDZ-UHFFFAOYSA-N 2-ethynyl-7h-purine Chemical compound C#CC1=NC=C2NC=NC2=N1 JCAFIKMITONRDZ-UHFFFAOYSA-N 0.000 description 1
- DOYKTCZGOFJYRT-UHFFFAOYSA-N 2-methylsulfanyl-4,5-dioxo-1,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1C(SC)=NC(=O)C2=C1NC=C(C(O)=O)C2=O DOYKTCZGOFJYRT-UHFFFAOYSA-N 0.000 description 1
- GEVCSRLIETZLTD-UHFFFAOYSA-N 2-methylsulfanyl-7h-purine Chemical compound CSC1=NC=C2NC=NC2=N1 GEVCSRLIETZLTD-UHFFFAOYSA-N 0.000 description 1
- OTATZJORPBVZSV-UHFFFAOYSA-N 2-methylsulfonyl-7h-purine Chemical compound CS(=O)(=O)C1=NC=C2NC=NC2=N1 OTATZJORPBVZSV-UHFFFAOYSA-N 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- MZMXZDWSVQWARY-UHFFFAOYSA-N 2-piperidin-1-yl-7h-purine Chemical compound C1CCCCN1C1=NC=C(NC=N2)C2=N1 MZMXZDWSVQWARY-UHFFFAOYSA-N 0.000 description 1
- BFOTXKLYRVWLNO-UHFFFAOYSA-N 2-pyridin-3-yl-7h-purine Chemical compound N=1C=C2NC=NC2=NC=1C1=CC=CN=C1 BFOTXKLYRVWLNO-UHFFFAOYSA-N 0.000 description 1
- WNIUQEPIXYPMSZ-UHFFFAOYSA-N 2-pyrrolidin-1-yl-7h-purine Chemical compound C1CCCN1C1=NC=C(NC=N2)C2=N1 WNIUQEPIXYPMSZ-UHFFFAOYSA-N 0.000 description 1
- IBMKAHAMTOEZPI-UHFFFAOYSA-N 2-thiophen-3-yl-7H-purine Chemical compound S1C=C(C=C1)C1=NC=C2NC=NC2=N1 IBMKAHAMTOEZPI-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- SOFPIAMTOZWXKT-UHFFFAOYSA-N 2h-1,2,4-triazine-3-thione Chemical compound SC1=NC=CN=N1 SOFPIAMTOZWXKT-UHFFFAOYSA-N 0.000 description 1
- MRSZSPVVWPUESC-UHFFFAOYSA-N 3,6,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,3,7,9,11-pentaene Chemical compound N1=CCN2C=NC=3C(=C21)C=CN=3 MRSZSPVVWPUESC-UHFFFAOYSA-N 0.000 description 1
- LPHWCAUEPAUFHZ-UHFFFAOYSA-N 3,6-Dihydropyridine Chemical compound C1C=CCN=C1 LPHWCAUEPAUFHZ-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WFRXSXUDWCVSPI-UHFFFAOYSA-N 3h-benzimidazol-5-amine Chemical compound NC1=CC=C2NC=NC2=C1 WFRXSXUDWCVSPI-UHFFFAOYSA-N 0.000 description 1
- SLKBJTSZBVISAO-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridin-6-amine Chemical compound C1=NC(N)=CC2=C1N=CN2 SLKBJTSZBVISAO-UHFFFAOYSA-N 0.000 description 1
- CBKDCOKSXCTDAA-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1-benzothiophene Chemical compound C1CCCC2=C1C=CS2 CBKDCOKSXCTDAA-UHFFFAOYSA-N 0.000 description 1
- LUNUNJFSHKSXGQ-UHFFFAOYSA-N 4-Aminoindole Chemical compound NC1=CC=CC2=C1C=CN2 LUNUNJFSHKSXGQ-UHFFFAOYSA-N 0.000 description 1
- MUEOQEUSJMFYHV-UHFFFAOYSA-N 4-amino-1-methylpyrrole-2-carboxylic acid Chemical compound CN1C=C(N)C=C1C(O)=O MUEOQEUSJMFYHV-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 1
- MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 description 1
- FTWWVHHTRYGHLX-UHFFFAOYSA-N 4-nitro-1-propylpyrrole-2-carboxylic acid Chemical compound CCCN1C=C([N+]([O-])=O)C=C1C(O)=O FTWWVHHTRYGHLX-UHFFFAOYSA-N 0.000 description 1
- NEJMFSBXFBFELK-UHFFFAOYSA-N 4-nitro-1h-benzimidazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1N=CN2 NEJMFSBXFBFELK-UHFFFAOYSA-N 0.000 description 1
- LAVZKLJDKGRZJG-UHFFFAOYSA-N 4-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=CC2=C1C=CN2 LAVZKLJDKGRZJG-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- BDTRIDKONHOQQN-UHFFFAOYSA-N 4h-pyrimidin-5-one Chemical compound O=C1CN=CN=C1 BDTRIDKONHOQQN-UHFFFAOYSA-N 0.000 description 1
- UFIOWTNUEWWUAQ-UHFFFAOYSA-N 5-amino-1-[(2-methylpropan-2-yl)oxycarbonyl]indole-2-carboxylic acid Chemical compound NC1=CC=C2N(C(=O)OC(C)(C)C)C(C(O)=O)=CC2=C1 UFIOWTNUEWWUAQ-UHFFFAOYSA-N 0.000 description 1
- JEDKNHDBCFKCDJ-UHFFFAOYSA-N 6-(1h-pyrrol-3-yl)-7h-purine Chemical compound N1C=CC(C=2C=3NC=NC=3N=CN=2)=C1 JEDKNHDBCFKCDJ-UHFFFAOYSA-N 0.000 description 1
- ACPXQMYLXLKGKU-UHFFFAOYSA-N 6-(azetidin-1-yl)-7h-purine Chemical compound C1CCN1C1=NC=NC2=C1NC=N2 ACPXQMYLXLKGKU-UHFFFAOYSA-N 0.000 description 1
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical compound O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 description 1
- WKQYPPBYOJEUEH-UHFFFAOYSA-N 6-cyclopropyl-7h-purin-2-amine Chemical compound C=12NC=NC2=NC(N)=NC=1C1CC1 WKQYPPBYOJEUEH-UHFFFAOYSA-N 0.000 description 1
- ZWKPDVVCMNKMHO-UHFFFAOYSA-N 6-ethynyl-7h-purine Chemical compound C#CC1=NC=NC2=C1NC=N2 ZWKPDVVCMNKMHO-UHFFFAOYSA-N 0.000 description 1
- ZMYMWRORNQVELJ-UHFFFAOYSA-N 6-hydrazinyl-1h-pyrimidin-2-one Chemical compound NNC1=CC=NC(=O)N1 ZMYMWRORNQVELJ-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- LDORHCBMWSQLIU-UHFFFAOYSA-N 6-phenyl-1h-pyrimidin-2-one Chemical compound N1C(=O)N=CC=C1C1=CC=CC=C1 LDORHCBMWSQLIU-UHFFFAOYSA-N 0.000 description 1
- YZMFLXDRCYCBFD-UHFFFAOYSA-N 6-phenylpurin-6-amine Chemical compound N1=CN=C2N=CN=C2C1(N)C1=CC=CC=C1 YZMFLXDRCYCBFD-UHFFFAOYSA-N 0.000 description 1
- OXCZAXJFRBPQRP-UHFFFAOYSA-N 6-piperidin-1-yl-7h-purine Chemical compound C1CCCCN1C1=NC=NC2=C1NC=N2 OXCZAXJFRBPQRP-UHFFFAOYSA-N 0.000 description 1
- CWBOAMAHXROOMO-UHFFFAOYSA-N 6-pyrrol-1-yl-7h-purine Chemical compound C1=CC=CN1C1=C2N=CN=C2N=CN1 CWBOAMAHXROOMO-UHFFFAOYSA-N 0.000 description 1
- IQSRNEOAVVBNGN-UHFFFAOYSA-N 6-pyrrolidin-1-yl-7h-purine Chemical compound C1CCCN1C1=NC=NC2=C1NC=N2 IQSRNEOAVVBNGN-UHFFFAOYSA-N 0.000 description 1
- QCHLWIPINNRBSG-UHFFFAOYSA-N 6-thiophen-2-yl-7h-purin-2-amine Chemical compound C=12NC=NC2=NC(N)=NC=1C1=CC=CS1 QCHLWIPINNRBSG-UHFFFAOYSA-N 0.000 description 1
- HHIGXLUQAAVVGO-UHFFFAOYSA-N 6-thiophen-3-yl-1h-pyrimidin-2-one Chemical compound C1=CNC(=O)N=C1C1=CSC=C1 HHIGXLUQAAVVGO-UHFFFAOYSA-N 0.000 description 1
- HNWRZHRRVBORIS-UHFFFAOYSA-N 6-thiophen-3-yl-7h-purine Chemical compound S1C=CC(C=2C=3N=CNC=3N=CN=2)=C1 HNWRZHRRVBORIS-UHFFFAOYSA-N 0.000 description 1
- RSCLTFBAFSPPJB-UHFFFAOYSA-N 6h-pteridin-7-one Chemical compound C1=NC=NC2=NC(=O)CN=C21 RSCLTFBAFSPPJB-UHFFFAOYSA-N 0.000 description 1
- GKNVWOWIFVSUFJ-UHFFFAOYSA-N 7-nitro-1h-imidazo[4,5-b]pyridine Chemical compound [O-][N+](=O)C1=CC=NC2=C1NC=N2 GKNVWOWIFVSUFJ-UHFFFAOYSA-N 0.000 description 1
- HOXPMFBXNMYFSM-UHFFFAOYSA-N 7h-purin-2-ylhydrazine Chemical compound NNC1=NC=C2NC=NC2=N1 HOXPMFBXNMYFSM-UHFFFAOYSA-N 0.000 description 1
- IUEISQYNCXVHTJ-UHFFFAOYSA-N 7h-purin-6-ylhydrazine Chemical compound NNC1=NC=NC2=C1NC=N2 IUEISQYNCXVHTJ-UHFFFAOYSA-N 0.000 description 1
- FWIPENNQZPWMFI-UHFFFAOYSA-N 7h-purine-6-carbothioamide Chemical compound NC(=S)C1=NC=NC2=C1NC=N2 FWIPENNQZPWMFI-UHFFFAOYSA-N 0.000 description 1
- FVXHPCVBOXMRJP-UHFFFAOYSA-N 8-bromo-7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC(Br)=N2 FVXHPCVBOXMRJP-UHFFFAOYSA-N 0.000 description 1
- CVSGHIRICCUQKF-UHFFFAOYSA-N 8-bromo-7h-purine Chemical compound C1=NC=C2NC(Br)=NC2=N1 CVSGHIRICCUQKF-UHFFFAOYSA-N 0.000 description 1
- MXPGBTNMLVKYPM-UHFFFAOYSA-N 8-cyclopropyl-7h-purin-2-amine Chemical compound N=1C2=NC(N)=NC=C2NC=1C1CC1 MXPGBTNMLVKYPM-UHFFFAOYSA-N 0.000 description 1
- SDKMTBMGPHLMQD-UHFFFAOYSA-N 8-thiophen-2-yl-7H-purin-2-amine Chemical compound S1C(=CC=C1)C1=NC2=NC(=NC=C2N1)N SDKMTBMGPHLMQD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- GCLGKPHBJPABBF-UHFFFAOYSA-N N1(CCC1)C1=NC=C2NC=NC2=N1 Chemical compound N1(CCC1)C1=NC=C2NC=NC2=N1 GCLGKPHBJPABBF-UHFFFAOYSA-N 0.000 description 1
- XTKTUSAYZWTBAX-UHFFFAOYSA-N N1CNCC2=C1N=CC(=C2)C(=O)N Chemical compound N1CNCC2=C1N=CC(=C2)C(=O)N XTKTUSAYZWTBAX-UHFFFAOYSA-N 0.000 description 1
- BUIQRTDBPCHRIR-UHFFFAOYSA-L O[Cr](Cl)(=O)=O Chemical compound O[Cr](Cl)(=O)=O BUIQRTDBPCHRIR-UHFFFAOYSA-L 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000005276 alkyl hydrazino group Chemical group 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000005018 aminopurines Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical compound N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- INVKHBRFFCQICU-VIFPVBQESA-N ditert-butyl (2s)-5-oxopyrrolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)[C@@H]1CCC(=O)N1C(=O)OC(C)(C)C INVKHBRFFCQICU-VIFPVBQESA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 231100000351 embryotoxic Toxicity 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical class [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- YEWYVRQMZKOENB-UHFFFAOYSA-N n-cyclohexyl-7h-purin-6-amine Chemical compound C1CCCCC1NC1=NC=NC2=C1NC=N2 YEWYVRQMZKOENB-UHFFFAOYSA-N 0.000 description 1
- LMWYJWNGVLKEDL-UHFFFAOYSA-N n-cyclopentyl-7h-purin-6-amine Chemical compound C1CCCC1NC1=NC=NC2=C1NC=N2 LMWYJWNGVLKEDL-UHFFFAOYSA-N 0.000 description 1
- ZVXQITNIMKKBBE-UHFFFAOYSA-N n-cyclopropyl-7h-purin-6-amine Chemical compound C1CC1NC1=NC=NC2=C1N=CN2 ZVXQITNIMKKBBE-UHFFFAOYSA-N 0.000 description 1
- PNUJBVDTPXKNDZ-UHFFFAOYSA-N n-methyl-2h-pyridin-1-amine Chemical compound CNN1CC=CC=C1 PNUJBVDTPXKNDZ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- QXSAKPUBHTZHKW-UHFFFAOYSA-N para-hydroxybenzamide Natural products NC(=O)C1=CC=C(O)C=C1 QXSAKPUBHTZHKW-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- AWZPRFJPTISADL-UHFFFAOYSA-N pteridine-6-carboxamide Chemical compound N1=CN=CC2=NC(C(=O)N)=CN=C21 AWZPRFJPTISADL-UHFFFAOYSA-N 0.000 description 1
- WABAALFDOOSQEE-UHFFFAOYSA-N pteridine-6-carboxylic acid Chemical compound N1=CN=CC2=NC(C(=O)O)=CN=C21 WABAALFDOOSQEE-UHFFFAOYSA-N 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 150000003214 pyranose derivatives Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
- 239000002718 pyrimidine nucleoside Chemical class 0.000 description 1
- KYPREUXQEYJYPR-UHFFFAOYSA-N pyrimidine-5-carboximidamide Chemical compound NC(=N)C1=CN=CN=C1 KYPREUXQEYJYPR-UHFFFAOYSA-N 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical class 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- GTJUPSNUGOBNMF-UHFFFAOYSA-M zinc;cyclopentane;bromide Chemical compound Br[Zn+].C1CC[CH-]C1 GTJUPSNUGOBNMF-UHFFFAOYSA-M 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
NUCLEOSIDE DERIVATIVES FOR TREATING
HEPATITIS C VIRUS INFECTION
The invention relates to the field of pharmaceutical chemistry, in particular to compounds, compositions and methods for treating hepatitis C virus infections.
The following publications and patents are cited in this application as superscript numbers: 1. Chen, ef al., Med. Assoc., 95(1):6-12 (1996) 2. Cornberg, et al., "Hepatitis C: therapeutic perspectives." Forum (Genova), 11(2):154-62 (2001) 3. Dymock, et al., Antivir. Chem. Chemother. 11(2):79-96 (2000) 4. Devos, et al., International Patent Application Publication No. WO 02/18404 A2, published 7 March 2002 5. Sommadossi, ef al., International Patent Application Publication No.
WO 01/90121, published 23 May 2001 6. Ducrocq, C.; et al., Tetrahedron, 32:773 (1976). 7. Rizkalla, B. H.; Broom, A. D., J. Org. Chem., 37(25):3980 (1972). 8. Anderson, G. L.; Broom, A. D., J. Org. Chem., 42(6):997 (1977). 1
Amended sheet 27/02/2007
® 9. Rizkalla, B.
H.; Broom, A.
D., J.
Org.
Chem., 37(25):3975 (1972).
10. Furukawa, Y.; Honjo, M., Chem.
Pharm.
Bull., 16(6):1076 (1968).
11. Ektova, L.
V.; et al, Bioorg.
Khim., 5:1369 (1979).
12. De Clercq, E.; et al., J.
Med.
Chem., 26(5):661 (1983).
13. Robins, M.
J.; Barr, P.
J., J.
Org.
Chem., 48(11):1854 (1983).
14. Griengl, H., J Med.
Chem.,28(11):1679 (1985).
15. Lichtenhaler, F.
W.; Cuny, E., Chem.
Ber., 114:1610 (1981).
16. Hamilton, H.
W.; Bristol, J.
A., J.
Med.
Chem., 26(11):1601 (1983).
17. Seela, F.; Steker, H., Liebigs Ann.
Chem., p. 1576 (1983).
18. Winkley, M.
W.; et al., J.
Heterocycl.
Chem., 8:237 (1971).
19. Barascut, J.
L.; et al., J.
Carbohydr.
Nucleosides Nucleotides,
3(5&6):281 (1976). 20. Kiriasis, L.; Pfleiderer, W., Nucleosides Nucleotides, 8(7):1345 (1989).
21. Schneider, H.-J.; Pfleiderer, W., Chem.
Berich., 107:3377 (1974).
22. Angew.
Chem.
Int.
Ed.
Engl., 35:1968 (1996)
23. Hildbrand, S.; et al., Helv.
Chim.
Acta, 79:702 (1996).
2 Amended sheet 27/02/2007 i
° 24. De Las Heras, F.; et al, J.
Heterocycl.
Chem., 13:175 (1976). 25. Tam, S.
Y-K.; et al., J.
Heterocycl.
Chem., 13:1305 (1976). 26. Chu, C.
K.; et al., J.
Heterocycl.
Chem., 17:1435 (1980). 27. De Bernardo, S.; Weigele, M., J.
Org.
Chem., 42(1):109 (1977). 28. Saureamid-Reaktionen, L.; Orthoamide, I., Chem.
Ber., 101:41 (1968). 29. Lim, M.-L; Klein, R.
S.; Fox, J.
J., Tet.
Lett.,21:1013 (1981). 30. Yamazaki, A.; et al., J.
Org.
Chem., 32:1825 (1967). 31. Yamazaki, A.; Okutsu, M., J.
Heterocycl.
Chem., 1978, 15:353 (1978) 32. Lim, M.-L; Klein, R.
S., Tet.
Lett., 22:25 (1981). 33. Bhattacharya, B.
K.; et al., Tet.
Lett., 27(7):815 (1986). 34. Grisis,N.S.; etal, J Med.
Chem., 33:2750 (1990). 35. Li, N-.S.; Tang, X.-Q.; Piccirilli, J.
A., Organic Letters, 3(7):1025 (2001). 36. Cristalli, G.; et al., J.
Med.
Chem., 30(9):1686 (1987). 37. Seela, F.; et al., Nucleosides Nucleotides, 17(4):729 (1998). 38. Sagi, G.; etal, J.
Med.
Chem. 35(24):4549 (1992). 39. Hawkins, M.
E.; et al., Nucleic Acids Research, 23(15):2872 : | Amended sheet 27/02/2007
® (1995). 40. Mandal, S.B., et al., Synth. Commun., 9:1239 (1993). 41. Witty, DR, et al., Tet. Lett, 31: 4787 (1990). 42. Ning, J. et al, Carbohydr. Res., 330:165 (2001). 43. Yokoyama, M., ef al., J. Chem. Soc. Perkin Trans. I, 2145 (1996). 44, Carroll, S.S., ef al, ., International Patent Application
Publication No. WO 02057287, published 25 July 2002 45. Carroll, S.S., er al., ., International Patent Application
Publication No. WO 02057425, published 25 July 2002
All of the above publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
State of the Art
Hepatitis C virus (HCV) causes a liver damaging infection that can lead to cirrhosis, liver failure or liver cancer, and eventually death. HCV is an enveloped virus containing a positive-sense single-stranded RNA genome of approximately 9.4 kb, and has a virion size of 30-60 nm.’
HCV is a major causative agent for post-transfusion and for sporadic non-A, non-B hepatitis. Infection by HCV is insidious in a high proportion of chronically infected (and infectious) carriers who may not experience clinical symptoms for many years.
HCV is difficult to treat and it is estimated that there are 500 million 4
Amended sheet 27/02/2007 f people infected with it worldwide. No effective immunization is currently ® available, and hepatitis C can only be controlled by other preventive measures such as improvement in hygiene and sanitary conditions and interrupting the route of transmission.
At present, the only acceptable treatment for chronic hepatitis C is interferon (IFN-alpha) and this requires at least six (6) months of treatment and/or ribavarin, which can inhibit viral replication in infected cells and also improve liver function in some people.
IFN-alpha belongs to a family of naturally occurring small proteins with characteristic biological effects such as antiviral, immunoregulatory and antitumoral activities which are produced and secreted by most animal nucleated cells in response to several diseases, in particular viral infections.
IFN-alpha is an important regulator of growth and differentiation affecting cellular communication and immunological control. Treatment of HCV with interferon, however, has limited long term efficacy with a response rate about 25%. In addition, treatment of HCV with interferon has frequently been associated with adverse side effects such as fatigue, fever, chills, headache, myalgias, arthralgias, mild alopecia, psychiatric effects and associated disorders, autoimmune phenomena and associated disorders and thyroid dysfunction.
Ribavirin (1-p-D-ribofuranosyl-1 H-1,2,-4-triazole-3-carboxamide), an inhibitor of inosine 5'-monophosphate dehydrogenase (IMPDH), enhances the efficacy of IFN-alpha in the treatment of HCV. Despite the introduction of ribavirin, more than 50% of the patients do not eliminate the virus with the current standard therapy of interferon-alpha (IFN) and ribavirin. By now, standard therapy of chronic hepatitis C has been changed to the combination of PEG-IFN plus ribavirin. However, a number of patients still have significant side effects, primarily related to ribaviran. Ribavirin causes significant hemolysis in 10-20% of patients treated at currently recommended doses, and the drug is both teratogenic and embryotoxic.
Other approaches are being taken to combat the virus. They include, for example, application of antisense oligonucleotides or ribozymes for > Amended sheet 27/02/2007 inhibiting HCV replication. Furthermore, low-molecular weight compounds ® that directly inhibit HCV proteins and interfere with viral replication are considered as attractive strategies to control HCV infection. NS3/4A serine protease, ribonucleic acid (RNA) helicase, RNA-dependent RNA polymerase are considered as potential targets for new drugs.”
Devos, ef al.* describes purine and pyrimidine nucleoside derivatives and their use as inhibitors of HCV RNA replication. Sommadossi, ef al.’ describes 1', 2' or 3'-modified nucleosides and their use for treating a host infected with HCV. Carroll, ef al* 4 both of which published after the filing of the present application, describe nucleosides as inhibitors of RNA- dependent RNA viral polymerase. Applicants do not intend to cover any compounds specifically disclosed in these applications.
Given the fact of the worldwide epidemic level of HCV, there is a strong need for new effective drugs for HCV treatment. The present invention provides nucleoside derivatives for treating HCV infections.
This invention is directed to novel compounds that are useful in the treatment of HCV in mammals. Specifically, the compounds of this invention are represented by formula Ia, Ib and Ic below:
R2 R?
SIL, xy
NTOONT TY oy T
R R? R R! R R?
OHOH OH OH OHOH la Ib Ic wherein R and R' are independently selected from the group consisting of: hydrogen, alkyl, 6 Amended sheet 27/02/2007
® substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl provided that R and R' are not both hydrogen;
R? is selected from the group consisting of: alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acylamino guanidino amidino thioacylamino, hydroxy, alkoxy, substituted alkoxy, halo, nitro, thioalkyl aryl, substituted aryl, heteroaryl, substituted heteroaryl, -NR’R* where R* and R* are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, 7 Amended sheet 27/02/2007
® substituted heteroaryl, heterocyclic, substituted heterocyclic and where R* and
R* are joined to form, together with the nitrogen atom bond thereto, a heterocyclic, substituted heterocyclic, heteroaryl, or substituted heteroaryl , -NR’NR’R* where R® and R* are as defined above and R® is selected from the group consisting of hydrogen and alkyl,
W is selected from the group consisting of: hydrogen, phosphate (including monophosphate, diphosphate, triphosphate or a stablilized phosphate prodrug), phosphonate, acyl, alkyl, sulfonate ester selected from the group consisting of alkyl esters, substituted alkyl esters, alkenyl esters, substituted alkenyl esters, aryl esters, substituted aryl esters, heteroaryl esters, substituted heteroaryl esters, heterocyclic esters and substituted heterocyclic esters, a lipid, an amino acid, a carbohydrate, a peptide, and cholesterol;
X is selected from the group consisting of: hydrogen, halo, alkyl, substituted alkyl, and -NR?R* where R? and R? are as identified above;
Y is selected from the group consisting of: hydrogen, halo, hydroxy, 8 Amended sheet 27/02/2007
® alkylthio -NR®R* where R® and R* are as identified above;
Z is selected from the group consisting of: hydrogen, halo, hydroxy, alkyl, azido, and -NR’R* where R® and R* are as identified above
NR’NR3R* where R® , R* and R® are as identified above; and wherein T is selected from the group consisting of a) 1- and 3- deazapurines of the formula below: 7 20) 7 20)
N—{ N— °N « N= or & — b) purine nucleosides of the formula below:
M
N R10
Wd « v={
Y kd ¢) benzimidazole nucleosides of the formula below:
N
“~~ 2 « (R?), d) 5-pyrrolopyridine nucleosides of the formula below:
N
J \ a SN y R20) N ) or ¥ (R20), e) 4-pyrimidopyridone sangivamycin analogs of the formula below: 9
Amended sheet 27/02/2007
® 2 9 I oy
NSN
¢ : f) 2-pyrimidopyridone sangivamycin analogs of the formula below: z (R29),
ZN o
OO” N Ny $ : g) 4-pyrimidopyridone sangivamycin analogs of the formula below: 0 a
ART), (R21), ON
N Ny $ : h) pyrimidopyridine analogs of the formulae below:
Q Q
JL) | (rm x ww ’ x Nd i
SENS LAA
N $ 0 N N° "0 or < ; i) pyrimido-tetrahydropyridines of the formula below:
Q
CF
~ N
NSN
« .
J) Furanopyrimidines (& tetrahydro furanopyrimidines) of the formulae below:
R12 R12 / RY 10 "0 R10
R ~~
BB 0
N Ay Sw or ;
Amended sheet 27/02/2007
® k) pyrazolopyrimidines of the formula below:
R20 7 N ee
N™ SN 1) pyrolopyrimidines of the formula below:
R20 7/1 N
A
NN
£0 m) triazolopyrimidines of the formula below:
Oo
N-<
N
¢ 9
NS
= : n) pteridines of the formula below:
Q
0 { Ny 0) pyridine C-nucleosides of the formula below:
I
(R)
Si = p) pyrazolotriazine C-nucleosides of the formula below: 11
Amended sheet 27/02/2007
®
Aw
Non xn” — —
Foy q) Indole nucleosides of the formula below:
R20 0) o r) a base of the formula below:
Y R20) n 2 . z—
N SN
$ : s) a base of the formula below:
Q
Y
{ Rto z oT N~
N No t) a base of the formula below:
R20
NAA
N R22 u) a base of the formula below: 12
Amended sheet 27/02/2007 o TQ
N rd
J
N : v) a base of the formula below:
R20 (R19)
N 1 N rd P
Xx s ~
Na w) a base of the formula below:
Q
N. N A, : x) a base of the formula below:
Q
“Cr =
N A, $ y) a base of the formula below:
M N
REA
& =I TR ) n* 13
Amended sheet 27/02/2007
® and further wherein one of bonds characterized by --- is a double bond and the other is a single bond provided that, when the --- between the N and a ring carbon is a double bond, then p is 0 and when the --- between Q and a ring carbon is a double bond, then pis 1; each p is independently 0 or 1; each n is independently 0 or an integer from 1 to 4; each n* is independently 0 or an integer from 1 to 2;
L is selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, amino, substituted amino, azido, and nitro;
Q is selected from the group consisting of hydrogen, halo, =O, -OR'"! =N-R'!, -NHR'! =S, -SR"", aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
M is selected from the group consisting of =O, =N-R'!, and =S;
Y is as defined above;
R'is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, alkylthioether, substituted alkylthioether, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, with the proviso that when T is b), s), v), w) or x), then R'® is not hydrogen; each R'' and R'is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, amino, substituted amino, alkylthioether, substituted alkylthioether, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; each R? is independently selected from the group consisting of? hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, alkenyl, 1 Amended sheet 27/02/2007
[ substituted alkenyl, alkynyl, substituted alkynyl, heteroaryl, substituted heteroaryl, acylamino guanidino amidino thioacylamino, alkoxy, substituted alkoxy, alkylthio, nitro, halo, hydroxy -NR’R* where R? and R* are as defined above,
NR°NR’R? where R® , R* and R® are as defined above; each R?' and R* are independently selected from the group consisting of: -NR3R* where R? and R* are as defined above, and -NR°NR’R* where R® , R* and R’ are as defined above -C(ONR’R? where R® and R* are as defined above, and -C(O)NR’NR? R* where R?, R* and R® are as defined above; and pharmaceutically acceptable salts thereof; with the provisos that 1) for a compound of formula Ia, when Z is hydrogen, halo, hydroxy, azido, or NR’R*, where R? and R* are independently H, or alkyl; Y is hydrogen or -NR’R* where R? and R* are independently hydrogen or alkyl; then R? is not alkyl, alkoxy, halo, hydroxy, CFs, or -NR’R* where R® and R* are independently hydrogen or alkyl; 2) for a compound of formula Ia, when Z is hydrogen, halo, hydroxy, azido, or NR’R*, where R? and R* are independently H, or alkyl; Y is hydrogen, halo, hydroxy, or alkylthio; then R? is not alkyl, 1 Amended sheet 27/02/2007
® substituted alkyl, wherein the substituted alkyl is substituted with hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected or protected, halo, hydroxy, alkoxy, thioalkyl, or -NR’R*, where R® and R* are independently hydrogen, alkyl or alkyl substituted with hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected or protected); 3) for a compound of formula Ib, when X is hydrogen, halo, alkyl, CF; or -NR’R* where R® is hydrogen and R* is alkyl, then R? is not alkyl, alkoxy, halo, hydroxy, CFs, or -NR’R* where R? and R* are independently hydrogen or alkyl;and 4) for a compound of formula Ib, RZis not, halo, alkoxy, hydroxy, thioalkyl, or -NR*R* (where R® and R* are independently hydrogen, alkyl or alkyl substituted with hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected or protected)
And further provided that the compound of Formual Ia, Ib or Ic is not a) 2-Hydroxymethyl-5-(6-phenyl-purin-9-yl)-tetrahydro-furan-3,4-diol; or b) b) 2-Hydroxymethyl-5-(6-thiophen-3-yl-purin-9-yl)-tetrahydro-furan-3,4- diol.
In a preferred embodiment R' is selected from the group consisting of -CH3, -CF3, -CH=CH,, and -C=CH, more preferrably CHs.
In another preferred embodiment when T is a base of formula a) then
T is a 3-deazapurine.
This invention is further directed to a compound of Formula II: 16 Amended sheet 27/02/2007
® VAR
C(Hb Y? ~ 7
N
B oS E
AD |]
N =F
WO
0)
R R!
OH OH
I wherein R and R' are independently selected from the group consisting of: hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, azido, amino, and substituted amino; provided that R and R' are not both hydrogen;
Y? is CH,, N, S, SO, or SO;
N together with -C(H)y, and Y? forms a heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl group wherein each of said heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl group is optionally fused to form a bi- or multi-fused ring system (preferably no more than 5 fused rings) with one or more ring structures selected from the group consisting of cycloalkyl, cycloalkenyl, heterocyclic, aryl and heteroaryl group which, in turn, each of such ring structures is optionally substituted with 1 to 4 substituents selected from the group consisting of hydroxyl, halo, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, aryl, heteroaryl, heterocyclic, nitro, cyano, carboxyl, carboxyl esters, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amino, 17
Amended sheet 27/02/2007
® and substituted amino; b is an integer equal to 0 or 1;
A, B, D, and E are independently selected from the group consisting of >N, >CH, >C-CN, >C-NO,, >C-alkyl, >C-substituted alkyl, >C-NHCONH3,, >C-CONR"R'¢, >C-COOR"?, >C-hydroxy, >C-alkoxy, >C-amino, >C- alkylamino, >C-dialkylamino, >C-halogen, >C-(1,3-oxazol-2-yl), >C-(1,3- thiazol-2-yl) and >C-(imidazol-2-yl);
F is selected from >N, >C-CN, >C-NQO,, >C-alkyl, >C-substituted alkyl, >C-NHCONH,, >C-CONR'’R'S, >C-COOR", >C-alkoxy, >C-(1,3-oxazol-2-yl), >C-(1,3-thiazol-2-yl), >C-(imidazol-2-yl), and >C-Y, where Y is selected from the group consisting of hydrogen, halo, hydroxy, alkylthioether, and -NR’R* where R? and R? are independently selected from the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R* and R* are joined to form, together with the nitrogen atom bond thereto, a heterocyclic group, provided that only one of R? and R* are hydroxy, alkoxy, or substituted alkoxy;
R' and R'® are independently selected from the group consisting of: hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and
R" and R'® together with the atom to which they are attached may form a cycloalkyl, substituted cycloalkyl, hetercycloalkyl, substituted heterocylcoalkyl, heteroaryl, or substituted heteroaryl,
W is selected from the group consisting of’: 18 Amended sheet 27/02/2007
C hydrogen, phosphate (including monophosphate, diphosphate, triphosphate or a stablilized phosphate prodrug), phosphonate, acyl, alkyl, sulfonate ester selected from the group consisting of alkyl esters, substituted alkyl esters, alkenyl esters, substituted alkenyl esters, aryl esters, substituted aryl esters, heteroaryl esters, substituted heteroaryl esters, heterocyclic esters and substituted heterocyclic esters, a lipid, an amino acid, a carbohydrate, a peptide, and cholesterol; and pharmaceutically acceptable salts thereof.
In a preferred embodiment, the compounds of formula 11 are represented by formula IIA:
Ny = Tr
WO
(0)
OHOH
HA wherein R and R' are independently selected from the group consisting of: hydrogen, alkyl, 19 Amended sheet 27/02/2007
® substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, azido, amino, and substituted amino; provided that R and R' are not both hydrogen;
Y? is CHa, N, S, SO, or SO;
N together with -C(H), and Y* forms a heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl group wherein each of said heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl group is optionally fused to form a bi- or multi-fused ring system (preferably no more than 5 fused rings) with one or more ring structures selected from the group consisting of cycloalkyl, cycloalkenyl, heterocyclic, aryl and heteroaryl group which, in turn, each of such ring structures is optionally substituted with 1 to 4 substituents selected from the group consisting of hydroxyl, halo, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, aryl, heteroaryl, heterocyclic, nitro, cyano, carboxyl, carboxyl esters, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amino, and substituted amino; b is an integer equal to 0 or 1;
W is selected from the group consisting of? hydrogen, phosphate (including monophosphate, diphosphate, triphosphate or a stablilized phosphate prodrug), phosphonate, acyl, alkyl, sulfonate ester selected from the group consisting of alkyl esters, substituted alkyl esters, alkenyl esters, substituted alkenyl esters, aryl
Amended sheet 27/02/2007
® esters, substituted aryl esters, heteroaryl esters, substituted heteroaryl esters, heterocyclic esters and substituted heterocyclic esters, a lipid, an amino acid, a carbohydrate, a peptide, and cholesterol;
Y is selected from the group consisting of Y is selected from the group consisting of: hydrogen, halo, hydroxy, alkylthioether -NR’R* where R? and R* are independently selected from the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R® and R? are joined to form, together with the nitrogen atom bond thereto, a heterocyclic group, provided that only one of R® and R* are hydroxy, alkoxy, or substituted alkoxy;
Z is selected from the group consisting of: hydrogen, halo, hydroxy, alkyl, azido, and -NR’R* where R® and R* are independently selected from the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R? and R* are joined to form, together with the nitrogen atom bond thereto, a heterocyclic group, provided that only one of R? and R* are hydroxy, alkoxy, or 21 Amended sheet 27/02/2007 substituted alkoxy; ® and pharmaceutically acceptable salts thereof.
Compounds included within the scope of this invention include, for example, those set forth below (including pharmaceutically acceptable salts thereof):
Smee we @ ¢ SN 9-(2’-C-methyl-B-D-ribofuranosyl)-
Thy N 6-(thiophen-3-yl)-purine
HO OH
US
) & SN 9-(2°-C-methyl-B-D-ribofuranosyl)- ly NN, 6-(thiophen-2-yl)-2-aminopurine
HO OH
H
[) 3 SN 9-(2’-C-methyl-B-D-ribofuranosyl)- “1 N° 6-(pyrrol-3-yl)-purine
HO OH
>» : N 9-(2’-C-methyl-B-D-ribofuranosyl)- “19 NZ, 2-amino-6-phenyl-purine
HO OH
CN
Y N 9-(2’-C-methyl-B-D-ribofuranosyl)-
Thy ND 6-(3-cyanophenyl)-purine
HO OH
22
Amended sheet 27/02/2007 oy ® _ el oN 9-(2’-C-methyl-B-D-ribofuranosyl)- “1 nN 6-(pyridin-3-yl)-puring
HO OH s 4 9-(2’-C-methyl-B-D-ribofuranosyl)- 7 OT "t 6-(benzo[b]thiophen-3-yl)-2-
HO oN Nk, + aminopurine
HO OH
HN—
N 9-(2’-C-methyl-B-D-ribofuranosyl)-
SSN
1) LA 6-(1H-indol-5-yl)-purine
HO OH y C 9-(2’-C-methyl-B-D-ribofuranosyl)-
Ho < SN J) 6-(naphthalen-2-yl)-purine
BY)
HO OH
0 ) 9-(2’-C-methyl-f-D-ribofuranosyl)-
OT 6-(dibenzofuran-4-yl)-2- “1 NT NH . . 2 aminopurine
HO OH x,
S
1 J; a 9-(2’-C-methyl-B-D-ribofuranosyl)- : BL nN 6-(thianthren-1-yl)-purine
HO OH
23
Amended sheet 27/02/2007 a - oh 9-(2’-C-methyl-B-D-ribofuranosyl)- 1) N" NH, 6-cyclopropyl-2-aminopurine
HO OH é | oN 9-(2’-C-methyl-B-D-ribofuranosyl)-
EY N 6-(ethynyl)-purine
HO OH s [}
I 7-(2’-C-methyl-B-D-ribofuranosyl)- wo Si , PB) 4-thiophen-3-yl-7H-pyrrolo[2,3- 9 d]pyrimidine
HO OH
7-(2’-C-methyl-B-D-ribofuranosyl)- 4 ~N - TH. -
HO oN | \ A 4-phenyl-7H-pyrrolo|2,3
IK) : d]pyrimidin-2-ylamine
HO OH
S
/ ZZ 17 | Be 1-(2’-C-methyl-B-D-ribofuranosyl)-
Thy ° 4-thiophen-3-yl-1H-pyrimidin-2-one
HO OH e 1-(2°-C-methyl-B-D-ribofuranosyl)-
HO I) Ao 4-phenyl-1H-pyrimidin-2-one
HO OH
24
Amended sheet 27/02/2007
NS 1-(2°-C-Methyl-f-D-ribofuranosyl)-
SN 4-benzo[b]thiophen-2-yl-1H-
HO No imidin-2- ie) pyrimidin-2-one
HO OH
SN 1-(2’-C-methyl-B-D-ribofuranosyl)- 21 be ( yl-p yh)
HO iS} 0 4-cyclopentyl-1H-pyrimidin-2-one
HO OH
)
NNN oY y 9-(2’-C-methyl-B-D-ribofuranosyl)- 22 HO oN NZ 6 iE N”-(2-dimethylaminoethyl)-adenine
HO OH
HN ~~ NH:
N oN b he - Ho 4X 9-(2’-C-methyl-B-D-ribofuranosyl)- iE N° —(2-aminoethyl)adenine
HO OH
N
~~ 9-(2’-C-methyl-B-D-ribofuranosyl)- 24 oo a; N° —[2-(1H-indol-3-yl)- iu ethyl]adenine
HO OH
N » 9-(2’-C-methyl-B-D-ribofuranosyl)- no Si? 6 —[2-aminocarbonyl-(pyrrolidine-1- he yD)]-purine
HO OH
25
Amended sheet 27/02/2007 o HN NH, x 6) o C x, 1-(2’-C-methyl--D-ribofuranosyl)-
[6]
Re N*-(aminocarbonylmethyl)cytidine
HO OH
® y - & } 1-(2°-C-methyl-B-D-ribofuranosyl)-
HO Ty +o N*-[(pyridin-1 -yl)-methyl]cytidine
HO OH
NH,
TN N BS
HN 4 N ; ; A CT 9-(2’-C-methyl-B-D-ribofuranosyl)-
HO o NN Ne | (adenin-8-yi)-aminoethyl]
As adenine
HO OH
H
[SE 9-(2°-C-methyl-p-D-ribofuranosyl)- 31 Ne, N® —[(benzene-3,4,5- le " triol)methyl]adenine
HO OH
0 } NHN 9-(2’-C-methyl-p-D-ribofuranosyl)-
SN
32 wo ST) N° —[1-aminocarbonyl-2-(3H-indol- ie 3-yl)-ethyl]adenine
HO OH
26
Amended sheet 27/02/2007
HN
J 9-(2’-C-methyl-B-D-ribofuranosyl)- 33 ¢ Tr b 6-(1,3,4,9-tetrahydro-beta-carbolin- by N” 2-yl)purine
HO OH
No
ON 1-(2’-C-methyl-B-D-ribofuranosyl)- 34 Oy ° N* —[1-aminocarbonyl-2-(3H-indol-
HO N70 is 3-yl)-ethyl]cytosine
HO OH
F
" : d
Tl 1-(2’-C-methyl-B-D-ribofuranosyl)-
NH
® 4-(pentafluorophenyl-hydrazino)-
HO no «eq. is pyrimidin-2-one
HO OH
OH
OH orl 1-(2’-C-methyl-B-D-ribofuranosy!)-
HO N 4-[4-(3,4-dihydroxy-benzyl)-6,7- 37 Oy
HO— “NTO dihydroxy-3,4-dihydro-1H-
Is isoquinolin-2-yl]-pyrimidin-2-one
HO OH
=N es 1-(2’-C-methyl-B-D-ribofuranosyl)-
SN
38 Ho [3 N* -[ 2-(3H-indol-3-y1)-
Re ethyl]cytosine
HO OH
27
Amended sheet 27/02/2007
NH,
C WN
C he 1-(2’-C-methyl-B-D-ribofuranosyl)- 39 HO oN © 4
Rs N" —(2-aminoethyl)cytosine
HO OH
0. NH, wi 1-(2’-C-methyl-B-D-ribofuranosyl)- “N
HO 0, N*-(aminocarbonyl-isopropyl-
I€ methyl)cytidine
HO OH hae
OT 9-(2’-C-methyl-B-D-ribofuranosyl)- 53 Ty NO _{[(3H-indol-3-yl)-acetic acid]- le N hydrazide}adenine
HO OH oN
Os
HN 9-(2’-C-methyl-B-D-ribofuranosyl)-
N ES o Ae N® —[2-(5-fluoro-benzimidazol-1-
Ay yl)-ethyl]adenine
HO QOH
NH,
NH
T wo ¢ 7 9-(2’-C-methyl-p-D-ribofuranosyl)- he 6 —hydrazino-purine
HO OH un Cs
NSN 9-(2’-C-methyl-p-D-ribofuranosyl)- ¢ I
HO o NN N® (2,2,3,3,3,- pentafluoropropyl)adenine
HO OH
28
Amended sheet 27/02/2007
® CJ a, 9-(2’-C-methyl-B-D-ribofuranosyl)- 57 HO NN” ea. . ie 6-(piperidin-1-yl)purine
HO OH
N ae
Ho— ON 1-(2’-C-methyl-B-D-ribofuranosyl)- hey 1 H-benzimidazole
HO OH
NH
N AN
4 | _ 3-(2’-C-methyl-B-D-ribofuranosyl)- 61 HO o N N oy 3 H-imidazo[4,5-b]pyridin-7-ylamine
HO OH
HN NH,
N—SN 9-(2’-C-trifluoromethyl-B-D-
HO Ln? of N ribofuranosyl)-N°-(2-
Fs aminoethyl)adenine
HO OH
N s . oe 9-(2’-C-trifluoromethyl-f-D- 63 vo. CN ribofuranosyl)-N°®-[2-(3H-indol-3- [o] jo yl)-ethyl]adenine
HO OH lo 2 1 9-(2’-C-trifluoromethyl-B-D-
HO— JN nN? ribofuranosyl)-6-[2-aminocarbonyl- es (pyrrolidinc-1-yl)]-purine
HO OH
29
Amended sheet 27/02/2007
[e] ° D 9-(2’-C-trifl hyl-B-D -(2’-C-trifluoromethyl-B-D-
HO o N Po ( . 4 b hci ribofuranosyl)guanine
HO OH
N
(12 pe. Ho— ON 1-(2’-C-trifluoromethyl-B-D- hoy ribofuranosyl)-1H-benzimidazole
HO OH
Hn NH, ae
HO Sy [7 9-(2’-C-ethenyl-f-D-ribofuranosyl)- jos N®—(2-aminoethyl)adenine
HO OH
> _N poy 9-(2’-C-ethenyl-p-D-ribofuranosyl)- ¢ I
HO [A N®_[2-(3H-indol-3-yl)-ethyl]adenine
HO OH
0 2 Ty 9-(2’-C-ethenyl-B-D-ribofuranosyl)- 70 Ho— NW 6—[2-aminocarbonyl-(pyrrolidine-1- joZ yD}-purine
HO OH
N a2 3 HO oN 1-(2’-C-ethenyl-B-D-ribofuranosyl)- - 1 H-benzimidazole
HO OH
HN SNH; ae 4 HO SN LZ 9-(2’-C-ethynyl-B-D-ribofuranosyl)- jos N®—(2-aminoethyl)adenine
HO OH
Amended sheet 27/02/2007
® &, +s ry 9-(2’-C-ethynyl-B-D-nibofuranosyl)- gy NS_[2-(3H-indol-3-yl)-ethyl adenine we OH 0
N Ty 9-(2’-C-ethynyl-B-D-ribofuranosyl)- ¢ 76 HO a nN? 6—[2-aminocarbonyl-(pyrrolidine-1- 1 y1))-purine
HO OH
N ag - Ho— ON 1-(2’-C-ethynyl-B-D-ribofuranosyl)-
Ros 1 H-benzimidazole ud OH
Yr
N” NH, 5-(2’-C-methyl-p-D-ribofuranosyl)- “IY SH-pyrrolo[3,2-c]pyridin-4-ylamine
HO OH
0 0 NH, 4-Amino-8-(2’-C-methyl-B-D-
H,N ; ZY \ PNY J ribofuranosyl)-5-oxo-5,8-dihydro-
HO ie pyrido[2,3-d]pyrimidine-6- carboxylic acid amide
HO OH
0 O Nm, 2,4-Diamino-8-(2’-C-methyl-f-D-
TL ibof 1)-5-0%0-5,8-dihyd i o Ny - ribofuranosyl)-5-oxo-5,8-dihydro- oy pyrido[2,3-d]pyrimidine-6- carboxylic acid amide
HO OH
31
Amended sheet 27/02/2007
HN_ _O NH, ® LL 4-Amino-8-(2’-C-methyl-B-D- - oP Np ribofuranosyl)-7-0x0-7,8-dihydro-
HO— o pyrido[2,3-d]pyrimidine-5- carboxylic acid amide
HO OH
HNN__O NH
A 2,4-Diamino-8-(2’-C-methyl--D- ~ J ribofuranosyl)-7-oxo-7,8-dihydro- 07 “N7 NT NH,
HO— pyrido[2,3-d}pyrimidine-5- carboxylic acid amide
HO OH oO 0 oOo wp 8-(2’-C-methyl-B-D-ribofuranosyl)- . ENN 2-methylsulfanyl-4,5-dioxo-3,4,5,8-
HO o tetrahydro-pyrido[2,3-d]pyrimidine- 6-carboxylic acid amide
HO OH
) ~~ Tr 8-(2’-C-methyl-B-D-ribofuranosyl)- ~~ x
Ho. a NO 8H-pyrido[2,3-d]pyrimidine-2,4- 0 dione
HO OH
[0]
ST NH 1-(2’-C-methyl-B-D-ribofuranosyl)-
Cor, (Comey Dotan) 87 HO | 1H-pyrido[2,3-d]pyrimidine-2,4-
Tv dione
HO OH s oe } 8-(2’-C-methyl-B-D-ribofuranosyl)- 88 HO N SN 4-methylsulfanyl-5,6,7,8-tetrahydro- {0} 1 pyrido[2,3-d]pyrimidine
HO OH
32
Amended sheet 27/02/2007
® [3 3-(2’-C-methyl-f-D-ribofuranosyl)- o N"So 6-methyl-3,7a-dihydro-1H-furo[2,3-
K) d]pyrimidin-2-one
HO OH
0 oe NH 3-(2’-C-methyl-B-D-ribofuranosyl)-
Ho No 3,5,6,7a-tetrahydro-1H-furo[2,3- 8} d]pyrimidin-2-one
HO OH
Ss” 7 7-(2’-C-methyl-B-D-ribofuranosyl)- 92 HO— NSN” 4-methylsulfanyl-7H-pyrrolo[2,3- + d]pyrimidine
HO OH ss” fr N 1-(2’-C-methyl-B-D-ribofuranosyl)-
N= 93 HO o 4-methylsulfanyl-1H-pyrrolo[2,3- { \ d]pyrimidine
HO OH
O
MY 3-(2’-C-methyl-B-D-ribofuranosyl)-
Ho— o NON 3H-[1,2,4]triazolo[1,5-a)pyrimidin-
Hy 7-one
HO OH
0)
N ~
I + 3-methyl-8-(2’-C-methyl-B-D-
ONIN
HO 4 ribofuranosyl)-2-methylsulfanyl- he y 3H,8H-pteridine-4,7-dione
HO OH
33
Amended sheet 27/02/2007
SN
® > 5-(2’-C-methyl-3-D-ribofuranosyl)-
HO pyridin-2-ylamine
HO OH
0]
NH
5-(2’-C-methyl-B-D-ribofuranosyl)- 97 HO = 4 i 1 (5 V 1H-pyridin-2-one /
HO OH ig
N NSN 8-(2’-C-methyl-B-D-ribofuranosyl)-
HO— ow pyrazolo[1,5-a][1,3,5]triazin-4-
WV ylamine
HO OH
[e)
Noy 8-(2’-C-methyl-f3-D-ribofuranosyl)-
HO— 4 nN 3H-pyrazolo{1,5-a][1,3,5]triazin-4- he A one
HO OH
0)
Nov 2-Amino-8-(2’-C-methyl-B-D-
HO— Ne N” NH, ribofuranosyl)-3H-pyrazolo[1,5- { Al a][1,3,5]triazin-4-one
HO OH
NO, 7) 1-(2’-C-methyl-B-D-ribofuranosyl)-
HO—y 5 N tof 4-nitroindole
HO OH
NH,
J . (1) 1-(2°-C-methyl-B-D-ribofuranosyl)- 105 HO oN }
A$ 4-aminoindole
HO OH
34
Amended sheet 27/02/2007
® i 9-(2’-C-methyl-B-D-ribofuranosyl)-
Wl N®-[2-(1H-imidazol-4-yl)-
HN ethyl]purine
N ae ch
HO OH
107 OS 9-(2’-C-methyl-B-D-ribofuranosyl)-
N i 6-(azetidin-1-yl)purine an
WT
HO OH
) 9-(2’-C-methyl-p-D-ribofuranosyl)- \ L, 6-(pyrrolidin-1-yl)purine
J
WT
HO OH y a (2’-C-mcthyl-B-D-ribofuranosyl)- $y .
Ho W > hypoxanthine
HO OH
112 N— 9-(2’-C-methyl-B-D-ribofuranosyl)-
HN
OLY 6- N-methylhydrazinopurine
Bi
HO OH
113 Q 9-(2°-C-methyl-B-D-ribofuranosyl)-
N 6-(1,2,3,4-tctrahydropyridin-1-
N ~N ¢ Ts yl)purine
WT
HO OH
Amended sheet 27/02/2007
PS 9-(2’-C-methyl-B-D-ribofuranosyl)- 6-(1,2,3,4-tetrahydroisoquinolin-2- ~~ yl)purine yf ON
I =
HO OH
150 SCH, 9-(2’-C-methyl-B-D-ribofuranosyl)- % Tr N 6-methythio-purine 4
J of N =
HO OH
151 0 2’-C-methyl-B-D-ribofuranosyl-
Chiral
N uracil a 0)
HO OH
152 Chiral 0 2’-C-methyl-B-D-ribofuranosyl-
H,C 8 \ thymine
Vo
O
AY
HO OH
155 9-(2’-C-methyl-B-D-ribofuranosyl)-
Chiral 6-phenyladenine
NH
N ANY a8 oY 7
SY
HO OH
36
Amended sheet 27/02/2007
® 156 Chiral I j 9-(2’-C-methyl-B-D-ribofuranosyl)-
HN N 6-(2-(1H-imidazol-4-yl)-
N XN ethylamino)purine
CA)
Ho “oH 157 () 9-(2’-C-methyl-B-D-ribofuranosyl)-
Chiral 6-(2-piperidin-1-yl-
NGL (2-pip y ethylamino)purine
N NN
SP
Ho “oH 158 | Chiral 9-(2’-C-methyl-B-D-ribofuranosyl)- pe 6-(cyclopropylamino) purine
HN
N NN
1
BC
HO OH
159 1 9-(2’-C-methyl-B-D-ribofuranosyl)-
Chiral HN 6-(cyclopentylamino)purine
N NN ag
BT N
Ho on 37
Amended sheet 27/02/2007
® 160 0) 9-(2’-C-methyl-B-D-ribofuranosyl)-
Chiral 6-(cyclohexylamino)purine
N NN ay
Bol wo om 161 oc oo Oo 8-(2’-C-methyl-B-D-ribofuranosyl)-
N Nr NH, 4,5-dioxo-3,4,5,8-tetrahydro-
Ny SN pyrido[2,3-d]pyrimidine-6- oY carboxylic acid amide
OH OH
162 ci 7-(2’-C-methyl-B-D-ribofuranosyl)- ne Ji 4-chloro-pyrrolo[2,3-d]pyrimidine
WW
Ho on 163 F 9-(2’-C-methyl-B-D-ribofuranosyl)- 6-(6-fluoro-1,3,4,9-tetrahydro-f3-
A carbolin-2-yl)purine
N
N N ae
Bel : Ho OH 164 7) 9-(2’-C-methyl-B-D-ribofuranosyl)-
N 6-(3,6-dihydro-2H-pyridin-1- yl)purine
N ~ N
CA)
Bol
Ho OH 38
Amended sheet 27/02/2007
® 165 NH, 4-amino-8-(2’-C-methyl-f-D-
N “YL ribofuranosyl)-2-methylsulfanyl-8H-
NPN No pyrido[2,3-d]pyrimidin-7-one 0
HO oH oH 166 ] N 6-(2°-C-methyl-B-D-ribofuranosyl)- \ 1,3a,5,6-tetraaza-as-indacene
N | AN
LAL
®)
HO on "OH 168 NO, 3-(2’-C-methyl-B-D-ribofuranosyl)-
N
& 0 7-nitro-imidazo[4,5-b]pyridine
N —
HO N o}
H H
OH OH
0 2-(2’-C-methyl-p-D-ribofuranosyl)-
A N 2H-[1,2,4]triazine-3,5-dione
PN
OH OH
170 9-(2’-C-methyl-B-D-ribofuranosyl)- 6-phenyl-purine - N AN N <1
HO ey N
OH OH
39
Amended sheet 27/02/2007
® 171 Chiral ~~ NH, 4-amino-7-(2’-C-methyl-p-D- ae N ribofuranosyl)-pyrrolo[2,3-
HO A > d]pyrimidine
HO OH
172 NH, 5-amino-2-(2’-C-methyl-B-D-
A N ribofuranosyl)-4,5-dihydro-2H-
HO 03 N As [1,2,4]triazine-3-thione
OH OH
173 NH, 6-amino-9-(B-D-ribofuranosyi)-7,9-
NT XN dihydro-purin-8-one
CY
N= TN
HO “oH 174 NH, 5-amino-2-(2’-C-methyl-f-D-
A N ribofuranosyl)-2H-[1,2,4]triazin-3-
HO Ty A, one
OH OH
175 NO, 1-(2’-C-methyl-B-D-ribofuranosyl)-
A 4-nitro-benzoimidazole
HO ¢ ) N
OH OH
40
Amended sheet 27/02/2007
® 176 NH, 4-amino-1-(2’-C-methyl-f-D- ) ribofuranosyl)-benzimidazole wo ¢
N
:
OH OH
177 OH 1-(2’-C-methyl-B-D-ribofuranosyl)-
OL 4-hydroxy-1H-pyridin-2-one
OH OH
178 [ 9-(2’-C-methyl-f-D-ribofuranosyl)- —N NN hi 6-(tetramethylguanidino)purine
N
N AY
CT
WO
Ho om 179 NH, 4-amino-1-(2’-C-methyl-B-D-
J AN ribofuranosyl)pyrrolo[2,3-b]
Ho »
N N pyridine lo]
OH OH
182 NH, 4-Amino-8-(2’-C-methyl-B-D-
OL ribofuranosyl)-8H-pyrido[2,3-
NT No d]pyrimidin-7-one *\ "on
OH
41
Amended sheet 27/02/2007
® 183 Cl 1-(2’-C-methyl-B-D-ribofuranosyl)- ¢ 10] 4,6-dichloro-1H-imidazo[4,5-
HO 6) ZN c]pyridine
OH OH
184a ; DN \ 1-(2’-C-methyl-B-D-ribofuranosyl)- 4 184b 0) aa, 5-aminobenzimidazole at) “a0
HO OH a b 1-(2’-C-methyl-p-D-ribofuranosyl)- 6-aminobenzimidazole 185 NH, H 6-amino-8-(N'-methyl-hydrazino)-9-
NT Ns NT (B-D-ribofuranosyl)-purine
Py
N N bea OH
HO ’ OH
I \ 6-(B-D-ribofuranosyl)-1,3a,5,6-
N ry tetraaza-as-indacene
NE
>
HO ; “OH
OH
188 Q 7-(2’-C-methyl-B-D-ribofuranosyl)-
OR 3,7-dihydro-pyrrolo[2,3-
Sn TN d]pyrimidin-4-one “
HO 1 “on ‘OH 42
Amended sheet 27/02/2007
® 189 Va \ 4-amino-5-(B-D-ribofuranosyl)-2-
N
N J ([1,2,4]triazolyl)-pyrimidine
N Ay :
NN
HO 2%8 NH,
HO OH
FN 4-methylamino-5-(B-D-
NJ ribofuranosyl)-2-([1,2,4]riazolyl)-
N A pyrimidine
NS ve eB
HO OH
200 4-methylamino-5-(B-D- _NH " ribofuranosyl)-2-(N'-methyl-
NT hydrazino)-pyrimidine
Xn ~
HO NT N
HO OH
201 NH, 1-(2’-C-methyl-B-D-ribofuranosyl)- ¢ po 6-amino-1H-imidazo[4,5-c]pyridine
Ww ]
OH OH
203 A 7-(2’-C-methyl-B-D-ribofuranosyl)-
H, . " ee 4-0x0-4,7-dihydro-3H-pyrrolo[2,3- “Tay | > d]pyrimidine-5-carboxamidine
HO OH
43
Amended sheet 27/02/2007
® 204 “0 4-amino-5-(furan-2-yl)-7-(B-D- — z ribofuranosyl)-pyrrolo[2,3- 717 N Ca “oy SN J d]pyrimidine
HO OH
205 Ao 4-amino-5-(oxazol-2-yl)-7-(B-D- rr ribofuranosyl)-pyrrolo[2,3- 7/17 N a “oy SN© d]pyrimidine
HO OH
206 4-cyclopropylamino-1-(2’-C- a= yclopropy (
Oo methyl-B-D-ribofuranosyl)-1H- oe pyrimidin-2-one
HO OH
207 an 1-(2’-C-methyl-B-D-ribofuranosyl)- ® N 4-hydrazino-1H-pyrimidin-2-one
HO OH
208 HNO 9-(2°-C-methyl-B-D-ribofuranosyl)- vo ga purine-6-carboxamide
HO OH
209 HN 8 9-(2’-C-methyl-B-D-ribofuranosyl)- oy 9H-purine-6-carbothioic acid amide “Kr SN
Ho oH 44
Amended sheet 27/02/2007
® 210 cl 1-(2’-C-methyl-B-D-ribofuranosyl)- ap 4.6-dichloro-pyrrolo[3,2-c]pyridine “hy Ze)
OHOH
211 NH; 1-(2°-C-methyl-B-D-ribofuranosyl)-
TE
Thy “al c]pyridine
OHOH
212 NH, 1-(2’-C-methyl-B-D-ribofuranosyl)- a 4-amino-pyrrolo[3,2-c]pyridine
OHOH
213 Ci 4-Chloro-7-fluoro-1-(2’-C-methyl-f3- ae D-ribofuranosyl)imidazo[4,5-
Cl = c]pyridine
F
OHOH
214 NH, 4-Amino-7-fluoro-1-(2’-C-methyl-f3- "vo < OJ D-ribofuranosyl)imidazo © F [4,5-c]pyridine
OHOH
215 yo NH 4-amino-7-(2’-C-methyl-p-D-
Ho ribofuranosyl)-5H-pyrrolo[3,2- oj MN d]pyrimidine
OHOH
3 Amended sheet 27/02/2007
® 216 NH, 4-Amino -1-(B-D-
N ES
¢ yg; ribofuranosyl)imidazo[4,5- ey ‘1 c]pyridine
OHOH
217 cl 4-Chloro-7-fluoro-1-(B-D-
N EN
¢ 70 ribofuranosyl)imidazo([4,5-
HO o NT ys ke F c]pyridine
OHOH
218 NH, 4-Amino-7-fluoro-1-(p-D- l | SN ribofuranosyl)imidazo[4,5-
HO— NT c]pyridine ie ]
OHOH
219 NH, 4-amino-6-methyl-7-(B-D-
De, ribofuranosyl)-pyrrolo[2,3-
N Ng d]pyrimidine
Oo
HO . “on
OH
220 NH, 4-amino-6-methyl-7-(2’-C-methyl-
Nee, B-D-ribofuranosyl)-pyrrolo[2,3-
N Ng d]pyrimidine
[0]
HO . “on
OH
221 NH, 0 4-Amino-8-(B-D-ribofuranosyl)-7-
N
“OY a 0x0-7,8-dihydro-pteridine-6-
N o “oo carboxylic acid amide oO “oH
OH
46
Amended sheet 27/02/2007
® 222 NH, 0 4-Amino-8-(2’-C-methyl-B-D-
AN oY Sw ribofuranosyl)-7-oxo-7,8-dihydro-
NY
NS vO pteridine-6-carboxylic acid amide oC “oH 223 NH, 0 O 4-Amino-8-(B-D-ribofuranosyl)-5-
YY 0x0-5,8-dihydro-pyrido[2,3-
S \ d]pyrimidine-6-carboxylic acid w{, amide “OH 224 NH, OO 4-Amino-8-(2’-C-methyl-B-D-
SOR ribofuranosyl)-5-0xo-5,8-dihydro-
NA pyrido[2,3-d]pyrimidine-6- {> “oH carboxylic acid amide “oH 225 NH, O 4-Amino-8-(B-D-ribofuranosyl)-5- 0 0x0-5,8-dihydro-pyrido[2,3-
SNTON ig oe d]pyrimidine
HO ) L oH 226 NH, 0 4-Amino-8-(2’-C-methyl-B-D- 90 ribofuranosyl)-8H-pyrido[2,3-
N. \ d]pyrimidin-5-one
L
“OH 227 NH, 4-Amino-8-(B-D-ribofuranosyl)-8H-
N
OY 1 pteridin-7-one
STON No o
HO ; oH “OH 47
Amended sheet 27/02/2007
® 228 NH, 4- Amino-8-(f-D-ribofuranosyl)-8H-
QO! pyrido[2,3-d]pyrimidin-7-one
SNOT No [o]
HO ’ “oH “OH 229 NH, 4-Amino-8-(3-D-ribofuranosyl)-2-
PIL methylsulfanyl-8H-pyrido[2,3-
I Fe dlovrimidin-7 o ]pyrimidin-7-one
HO . “oH “oH 230 NH, a 4-Amino-8-(B-D-ribofuranosyl)-2-
N rr Som methylsulfanyl-7-oxo-7,8-dihydro-
Ng Ny N [e] . . . . . pteridine-6-carboxylic acid amide [o} > “oH “OH
This invention is also directed to pharmaceutical compositions comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound of Formula Ia, Ib, Ic, II, IIA, III, or IV or mixtures of one or more of such compounds.
This invention is still further directed to methods for treating HCV in mammals which methods comprise administering to a mammal diagnosed with HCV or at risk of developing HCV a pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound of Formula Ia, Ib, Ic, II, IIA, III, or IV or mixtures of one or more of such compounds.
In still another of its method aspects, this invention is directed to a method for preparing the compounds of formula III: 48
Amended sheet 27/02/2007
® NR3R4
N XN
= Fy
WO
0)
R R?
OH OH i where R, R', R3 R RY, W, X,Y and Z are as defined above which method comprises: (a) oxidizing a compound of formula IV
SRé
N XN
TS
N Py
WO
0]
R R1
OH OH
Vv where R® is selected from the group consisting of alkyl and aryl; (b) oxidizing the thio group to a sulfoxide or sulfone; and (©) contacting the oxidized compound prepared in (b) above with at least a stoichiometric equivalent of HNR*R* under conditions which result in formation of a compound of formula II wherein R? and R* are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R? and R* are joined to form, together with the nitrogen atom bond thereto, a heterocyclic group. 49
Amended sheet 27/02/2007
The invention is directed to compounds, compositions and methods for treating hepatitis C virus infections. However, prior to describing this invention in detail, the following terms will first be defined:
As used herein, "alkyl" refers to alkyl groups having from 1 to 10 carbon atoms, preferably from 1 to 5 carbon atoms and more preferably 1 to 3 carbon atoms.
This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n- butyl, t-butyl, n-pentyl and the like. "Substituted alkyl" refers to an alkyl group having from 1 to 3, and preferably 1 to 2, substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxyl, nitro, carboxyl, carboxyl esters, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic. "Alkoxy" refers to the group "alkyl-O-" which includes, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, -butoxy, sec-butoxy, n-pentoxy and the like. "Substituted alkoxy" refers to the group "substituted alkyl-O-". "Acyl" refers to the groups H-C(O)-, alkyl-C(O)-, substituted alkyl-C(O)-, alkenyl-C(O)-, substituted alkenyl-C(O)-, alkynyl-C(O)-, substituted alkynyl-C(O)- cycloalkyl-C(O)-, substituted cycloalkyl-C(O)-, aryl-C(O)-, substituted aryl-C(O)-, heteroaryl-C(O)-, substituted heteroaryl-C(O), heterocyclic-C(O)-, and substituted heterocyclic-C(O)- wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as 50
Amended sheet 27/02/2007
® defined herein. "Acylamino" refers to the group -C(O)NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where each R is joined to form together with the nitrogen atom a heterocyclic or substituted heterocyclic ring wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. "Acyloxy" refers to the groups alkyl-C(O)O-, substituted alkyl-C(O)O-, alkenyl-C(O)O-, substituted alkenyl-C(O)O-, alkynyl-C(O)O-, substituted alkynyl-
C(0)O-, aryl-C(0O)0O-, substituted aryl-C(O)O-, cycloalkyl-C(O)O-, substituted cycloalkyl-C(O)O-, heteroaryl-C(O)O-, substituted heteroaryl-C(O)O-, heterocyclic-
C(0O)O-, and substituted heterocyclic-C(O)O- wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. "Alkenyl" refers to alkenyl group preferably having from 2 to 6 carbon atoms and more preferably 2 to 4 carbon atoms and having at least 1 and preferably from 1-2 sites of alkenyl unsaturation. "Substituted alkenyl" refers to alkenyl groups having from 1 to 3 substituents, and preferably 1 to 2 substituents, selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxyl, nitro, carboxyl, carboxyl esters, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic. 1 Amended sheet 27/02/2007
® "Alkynyl" refers to alkynyl group preferably having from 2 to 6 carbon atoms and more preferably 2 to 3 carbon atoms and having at least 1 and preferably from 1- 2 sites of alkynyl unsaturation.
"Substituted alkynyl" refers to alkynyl groups having from 1 to 3 substituents, and preferably 1 to 2 substituents, selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxyl, nitro, carboxyl, carboxyl esters, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.
“Amino” refers to the group —-NH,.
“Substituted amino” refers to the group -NR'R"” where R' and R" are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R’ and R" are joined, together with the nitrogen bound thereto to form a heterocyclic or substituted heterocylic group provided that R’ and R” are both not hydrogen.
When R' is hydrogen and R” is alkyl, the substituted amino group is sometimes referred to herein as alkylamino.
When R' and R" are alkyl, the substituted amino group is sometimes referred to herein as dialkylamino.
"Amidino" refers to groups with the formula -C(=NR")NR'R" where R', R" and R" are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R' and R" are joined, together with the nitrogen bound thereto to form a heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl group.
The term amidino also refers to reverse amidino structures of the formula:
> Amended sheet 27/02/2007
NR' ° _-
NR"): where R"" is an alkyl or substituted alkyl group as defined above and R" and R' are as defined above. "Guanidino" refers to groups with the formula -NHC(=NR"')NR'R" where R’,
R" and R™ are as defined above for amidino. "Aminoacyl" refers to the groups -NRC(O)alkyl, -NRC(O)substituted alkyl, -NRC(O)cycloalkyl, -NRC(O)substituted cycloalkyl, -NRC(O)alkenyl, -NRC(O)substituted alkenyl, -NRC(O)alkynyl, -NRC(O)substituted alkynyl, -NRC(O)aryl, -NRC(O)substituted aryl, -NRC(O)heteroaryl, -NRC(O)substituted heteroaryl, -NRC(O)heterocyclic, and -NRC(O)substituted heterocyclic where R is hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. "Aryl" or "Ar" refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2- benzoxazolinone, 2H-1,4-benzoxazin-3(4H)-one-7-yl, and the like). Preferred aryls include phenyl and naphthyl. “Substituted aryl” refers to aryl groups which are substituted with from 1 to 3 substituents, and preferably 1 to 2 substituents, selected from the group consisting of hydroxy, acyl, acylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, carboxyl, carboxyl esters, cyano, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thioheteroaryl, substituted thioheteroaryl, > Amended sheet 27/02/2007 thiocycloalkyl, substituted thiocycloalkyl, thioheterocyclic, substituted ® thioheterocyclic, cycloalkyl, substituted cycloalkyl, halo, nitro, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, and substituted heterocyclyloxy. "Aryloxy" refers to the group aryl-O- that includes, by way of example, phenoxy, naphthoxy, and the like. "Substituted aryloxy" refers to substituted aryl-O- groups. "Aryloxyaryl" refers to the group -aryl-O-aryl. "Substituted aryloxyaryl" refers to aryloxyaryl groups substituted with from 1 to 3 substituents on either or both aryl rings as defined above for substituted aryl. “Carboxyl” refers to COOH or salts therof. “Carboxyl esters” refers to the groups —C(0)O-alkyl, ~C(0)O-substituted alkyl, -C(O)Oaryl, and —-C(O)O-substituted aryl wherein alkyl, substituted alkyl, aryl and substituted aryl are as defined herein. "Cycloalkyl" refers to cyclic alkyl groups of from 3 to 10 carbon atoms having single or multiple cyclic rings including, by way of example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl and the like. "Cycloalkenyl" refers to cyclic alkeny! groups of from 4 to 10 carbon atoms having single or multiple cyclic rings and further having at least 1 and preferably from 1 to 2 internal sites of ethylenic (C=C) unsaturation. "Substituted cycloalkyl" and "substituted cycloalkenyl" refers to an cycloalkyl or cycloalkenyl group, having from 1 to 5 substituents selected from the group 54
Amended sheet 27/02/2007
PY consisting of oxo (=0), thioxo (=S), alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxyl, nitro, carboxyl, carboxyl esters, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic. "Cycloalkoxy" refers to -O-cycloalkyl groups. "Substituted cycloalkoxy" refers to -O-substituted cycloalkyl groups. "Halo" or "halogen" refers to fluoro, chloro, bromo and iodo and preferably is fluoro or chloro. "Heteroaryl" refers to an aromatic group of from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms, and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur within the ring. Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl). Preferred heteroaryls include pyridyl, pyrrolyl, indolyl, thiophenyl, and furyl. "Substituted heteroaryl" refers to heteroaryl groups that are substituted with from 1 to 3 substituents selected from the same group of substituents defined for substituted aryl. " "Heteroaryloxy" refers to the group -O-heteroaryl and "substituted heteroaryloxy" refers to the group -O-substituted heteroaryl. "Heterocycle" or "heterocyclic" refers to a saturated or unsaturated group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms and from 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur or oxygen within the ring wherein, in fused ring systems, onc or more the rings can be aryl or heteroaryl. 55
Amended sheet 27/02/2007
"Substituted heterocyclic" refers to heterocycle groups that are substituted ® with from 1 to 3 of the same substituents as defined for substituted cycloalkyl.
Examples of heterocycles and heteroaryls include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydro- isoquinoline, 4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene, benzo[b]thiophene, morpholinyl, thiomorpholiny! (also referred to as thiamorpholinyl), piperidinyl, pyrrolidine, tetrahydrofuranyl, and the like. "Heterocyclyloxy" refers to the group -O-heterocyclic and "substituted heterocyclyloxy" refers to the group -O-substituted heterocyclic. “Phosphate” refers to the groups —OP(O)(OH), (monophosphate), -OP(O)(OH)OP(O)(OH), (diphosphate) and -OP(O)(OH)OP(O)(OH)OP(O)(OH), (triphosphate) or salts thereof including partial salts thereof. “Phosphonate” refers to the groups —OP(OR)(OH) or -OP(OR)(OR) or salts thereof including partial salts thereof. "Thiol" refers to the group -SH. "Thioalkyl" or “alkylthioether” or “thioalkoxy” refers to the group -S-alkyl. "Substituted thioalkyl" or “substituted alkylthiocther” or “substituted thioalkoxy” refers to the group -S-substituted alkyl. "Thiocycloalkyl" refers to the groups -S-cycloalkyl and "substituted 56
Amended sheet 27/02/2007
PY thiocycloalkyl" refers to the group -S-substituted cycloalkyl. "Thioaryl" refers to the group -S-aryl and "substituted thioaryl" refers to the group -S-substituted aryl. "Thioheteroaryl" refers to the group -S-heteroaryl and "substituted thioheteroaryl"” refers to the group -S-substituted heteroaryl. "Thioheterocyclic" refers to the group -S-heterocyclic and "substituted thioheterocyclic" refers to the group -S-substituted heterocyclic.
The term “amino acid” refers to a-amino acids of the formula
H,NCH(RYCOOH where R is alkyl, substituted alkyl or aryl. Preferably, the a-amino acid is one of the twenty naturally occurring L amino acids.
The term “carbohydrate” refers to oligosaccharides comprising from 2 to saccharide units. The particular saccharide units employed are not critical and include, by way of example, all natural and synthetic derivatives of glucose, galactose, N-acetylglucosamine, N-acetylgalactosamine, fucose, sialic acid, and the like. In addition to being in their pyranose form, all saccharide units described herein are in their D form except for fucose which is in its L form.
The term “lipid” is an art recognized term defined, for example, by
Lehninger, Biochemistry, 1970, at pages 189 et seq. which is incorporated herein by reference in its entirety.
The term “peptide” refers to polymers of a-amino acids comprising from about 2 to about 20 amino acid units, preferably from about 2 to about 10, more preferably from about 2 to about 5.
The term “stablilized phosphate prodrug” refers to mono-, di- and 57
Amended sheet 27/02/2007 tri-phosphate groups having one or more of the hydroxyl groups pendent ® thereto converted to an alkoxy, a substituted alkoxy group, an aryloxy or a substituted aryloxy group. "Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts of a compound, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
It is understood that in all substituted groups defined above, polymers arrived at by defining substituents with further substituents to themselves (e.g., substituted aryl having a substituted aryl group as a substituent which is itself substituted with a substituted aryl group, etc.) are not intended for inclusion herein. In such cases, the maximum number of such substituents is three. That is to say that each of the above definitions is constrained by a limitation that, for example, substituted aryl groups are limted to —substituted aryl-(substituted aryl)-substituted aryl.
Similarly, it is understood that the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with fluoro groups or a hydroxyl group alpha to ethenylic or acetylenic unsaturation). Such impermissible substitution patterns are well known to the skilled artisan.
General Synthetic Methods
The compounds of this invention may be prepared by various methods known in the art of organic chemistry in general and nucleoside and nucleotide analogue synthesis in particular. The starting materials for the syntheses are either readily available from commercial sources or are known or may be prepared by techniques 58
Amended sheet 27/02/2007
® known in the art. General reviews of the preparation of nucleoside and nucleotide analogues are included in the following:
Michelson A.M. “The Chemistry of Nucleosides and Nucleotides,” Academic Press,
New York, 1963.
Goodman L. “Basic Principles in Nucleic Acid Chemistry,” Academic Press, New
York, 1974, vol. 1, Ch. 2. “Synthetic Procedures in Nucleic Acid Chemistry,” Eds. Zorbach W. & Tipson R.,
Wiley, New York, 1973, vol. 1 & 2.
The synthesis of carbocyclic nucleosides has been reviewed by Agrofoglio et al. (Tetrahedron, 1994, 50, 10611).
The compounds of the present invention may be prepared using methods outlined in U.S. Provisional Application Serial Number 60/378,624, incorporated herein by referenence in its entirety.
The strategies available for synthesis of compounds of this invention include:
A. General Synthesis of 2°-C-Branched Nucleosides 2’-C-Branched ribonucleosides of the following structures: 59
Amended sheet 27/02/2007
® { [
N XN X
N NT Y oA
WO WO N
O 0
R! Ri
OHOH OHOH la Ib where R', R%, W, X,Y and Z are as defined above, can be prepared by one of the following general methods. 1 Convergent approach: Glycosylation of Nucleobase with Appropriately
Modified Sugar
The key starting material of this process is an appropriately substituted sugar with 2°-OH and 2’-H with the appropriate leaving group, for example an acyl group or a chloro, bromo, fluoro or iodo. The sugar can be purchased or can be prepared by any known means including standard epimerization, substitution, oxidation and reduction techniques. For example, commercially available 1,3,5- tri-O-benzoyl-a-
D-ribofuranose (Pfanstiel Laboratories, Inc.) can be used. The substituted sugar can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 2’-modified sugar. Possible oxidizing agents are, for example, Dess-Martin periodine reagent, Ac,O+ DCC in DMSO, Swern oxidation (DMSO, oxalyl chloride, triethylamine), Jones reagent (a mixture of chromic acid and sulfuric acid), Collins’s reagent (dipyridine Cr(VI) oxide, Corey’s reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO,, ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cly-pyridine, H,O-ammonium molybdate, NaBrO,-CAN, NaOC1 in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum #-butoxide with another ketone) and N-bromosuccinimide. 60
Amended sheet 27/02/2007
Coupling of an organometallic carbon nucleophile, such as a Grignard ® reagent, an organolithium, lithium dialkylcopper or R'-SiMe; in TBAF with the ketone with the appropriate non-protic solvent at a suitable temperature, yields the 2’- alkylated sugar. For example, R'"MgBr/TiCl, or R'MgBr/CeCl; can be used as described in Wolfe et al. 1997. J. Org. Chem. 62: 1754-1759. The alkylated sugar can be optionally protected with a suitable protecting group, preferably with an acyl, substituted alkyl or silyl group, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and
Sons, Second Edition, 1991.
The optionally protected sugar can then be coupled to the purine or pyrimidine base by methods well known to those skilled in the art, as taught by
Townsend Chemistry of Nucleosides and Nucleotides, Plenum Press, 1994. For example, an acylated sugar can be coupled to a silylated base with a Lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature. Alternatively, a halo-sugar can be coupled to a silylated base with the presence of trimethylsilyltriflate.
Scheme 1 below describes the alternative synthesis of a protected sugar that is useful for coupling to bases where the connection to the base is on a carbon atom instead of a nitrogen atom.
Scheme 1: Alternative Sugar Synthesis and Coupling ol Amended sheet 27/02/2007
Ph Ph
HO \ : \ 0 4
HO of Ph._ 0 0 Ph._O OH a b c
Ph— Ph
R Ph A [i LUE 7x he re
Ph. _O O___Ph Ph._0 OH Ph._O © f . q
Formation of sugar a in Scheme 1, above, is accomplished as described by
Mandal, S.B., et al., Synth. Commun., 1993, 9, page 1239, starting from commercial
D-ribose. Protection of the hydroxy! groups to form sugar b is described in Witty,
D.R, etal, Tet. Lett, 1990, 31, page 4787. Sugar ¢ and d are prepared using the method of Ning, J. et al., Carbohydr. Res., 2001, 330, page 165, and methods described herein. R, in Sugar e can be hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl. Particularly preferred R groups are methyl, trifluoromethyl, alkenyl and alkynyl. Sugar e is prepared by using a modification of the Grignard reaction withn RMgBr or other appropriate organometallic as described herein (with no Titanium/cerium needed). Finally the halogenated sugar used in the subsequent coupling reaction is prepared using the same protection method as used in to make sugar b above. The halogenation is described in Seela.'’
Subsequently, any of the described nucleosides can be deprotected by methods well known to those skilled in the art, as taught by Greene ef al. Protective
Groups in Organic Synthesis, Jon Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 2’-C-branched ribonucleoside is desired. 2. Linear Approach: Modification of a pre-formed nucleoside 62
Amended sheet 27/02/2007
The key starting material for this process is an appropriately substituted ® nucleoside with a 2’-OH and 2°-H. The nucleoside can be purchased or can be prepared by any known means including standard coupling techniques. The nucleoside can be optionally protected with suitable protecting groups, preferably with acyl, substituted alkyl or silyl groups, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John
Wiley and Sons, Second Edition, 1991.
The appropriately protected nucleoside can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 2°-modified sugar. Possible oxidizing agents are, for example, Dess-Martin periodine reagent, Ac;O+ DCC in DMSO, Swern oxidation (DMSO, oxaly! chloride, triethylamine), Jones reagent (a mixture of chromic acid and sulfuric acid), Collins’s reagent (dipyridine Cr(VI) oxide, Corey’s reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO, ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, C1,-pyridine, H,Oz-ammonium molybdate, NaBrO,-CAN, NaOCl in
HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-
Pondorf-Verley reagent (aluminum #-butoxide with another ketone) and N- bromosuccinimide. Coupling of an organometallic carbon nucleophile, such as a
Grignard reagent, an organolithium, lithium dialkylcopper or R'-SiMe; in TBAF with the ketone with the appropriate non-protic solvent at a suitable temperature, yields the appropriate substituted nucleoside.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic
Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 2°-C-branched ribonucleoside is desired.
In another embodiment of the invention, the L-enantiomers are desired. Therefore, the L-enantiomers can be corresponding to the compounds of the invention can be prepared following the same foregoing general methods, beginning with the 63 Amended sheet 27/02/2007 corresponding L-sugar or nucleoside L-enantiomer as starting material.
B. General Synthesis of 3°-C-Branched Nucleosides 3’-C-Branched ribonucleosides of the following structure:
R2 R2
N AN X
N =
WO WO N
0 0)
R R
OHOH OH OH la lb where R, R?, W, X, Y and Z are as defined above, can be prepared by one of the following general methods. 1. Convergent approach: Glycosylation of the nucleobase with an appropriately modified sugar
The starting material for this process is an appropriately substituted sugar with a 3’-OH and 3’-H, with the appropriate leaving group, for example an acyl group, methoxy group or a chloro, bromo, fluoro, iodo. The sugar can be purchased or can be prepared by any known means including standard epimerization, substitution, oxidation and reduction techniques. The substituted sugar can then be purchased or can be prepared by any known means including standard epimerization, substitution, oxidation and reduction techniques. The substituted sugar can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 3’-modified sugar. Possible oxidizing agents are, for example, Dess-Martin periodine reagent, Jones reagent (a mixture of chromic acid and sulfuric acid),
Collins’s reagent (dipyridine Cr(V1) oxide, Corey’s reagent (pyridinium 64
Amended sheet 27/02/2007 chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, ® MnQO,, ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, C1;-pyridine, H,O,-ammonium molybdate,
NaBrO,-CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum ¢-butoxide with another ketone) and N-bromosuccinimide.
Then coupling of an organometallic carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkylcopper or R-SiMes in TBAF with the ketone with the appropriate non-protic solvent at a suitable temperature, yields the 3’-
C-branched sugar. For example, RMgBr/TiCls or RMgBr/CeCl; can be used as described in Wolfe et al. 1997. J. Org. Chem. 62: 1754-1759. The 3’-C-branched sugar can be optionally protected with a suitable protecting group, preferably with an acyl or silyl group, by methods well known to those skilled in the art, as taught by
Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second
Edition, 1991.
The optionally protected sugar can then be coupled to the base by methods well known to those skilled in the art, as taught by Townsend Chemistry of
Nucleosides and Nucleotides, Plenum Press, 1994. For example, an acylated sugar can be coupled to a silylated base with a Lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature. Alternatively, a halo-sugar can be coupled to a silylated base with the presence of trimethylsilyltriflate.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic
Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 3’-C-branched ribonucleoside is desired.
Alternatively, deoxyribonucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those 05 Amended sheet 27/02/2007 skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, ® John Wiley and Sons, Second Edition, 1991, and then the 2°-OH can be reduced with a suitable reducing agent. Optionally, the 2’-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction. 2. Linear Approach: Modification of a pre-formed nucleoside
The key starting material for this process is an appropriately substituted nucleoside with a 3°-OH and 3’-H. The nucleoside can be purchased or can be prepared by any known means including standard coupling techniques. The nucleoside can be optionally protected with suitable protecting groups, preferably with acyl or silyl groups, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons,
Second Edition, 1991.
The appropriately protected nucleoside can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 3’-modified sugar. Possible oxidizing agents are, for example, Dess-Martin periodine reagent, Jones reagent (a mixture of chromic acid and sulfuric acid),
Collins’s reagent (dipyridine Cr(VI) oxide), Corey’s reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate,
MnO; ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl,-pyridine, H,0,-ammonium molybdate,
NaBrO;-CAN, NaOCl] in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum ¢-butoxide with another ketone) and N-bromosuccinimide.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic
Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 3’-C-branched ribonucleoside is desired. 66 Amended sheet 27/02/2007
Alternatively, deoxyribonucleoside is desired. To obtain these nucleosides, the ® formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis,
John Wiley and Sons, Second Edition, 1991, and then the 2’-OH can be reduced with a suitable reducing agent. Optionally, the 2’-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
In another embodiment of the invention, the L-enantiomers are desired.
Therefore, the L-enantiomers can be corresponding to the compounds of the invention can be prepared following the same foregoing general methods, beginning with the corresponding L-sugar or nucleoside L-enantiomer as starting material.
C._ General Synthesis of Purine Bases of Formula Ja and Pyrimidines Bases of
Formula Ib
The purine bases of formula 1-IVa and pyrimidines bases of formula I-IVb for above condensation reactions can be obtained commercially or can be prepared by procedures known to the art.
The preparation of purine bases of formula [-IVa is reviewed by G. Shaw in “Comprehensive Heterocyclic Chemistry,” Pergamon Press, Vol. 5, chapter 4.09, p. 449 and “Comprehensive Heterocyclic Chemistry II” Pergamon Press, Vol. 7, chapter 7.11, p. 397.
The preparation of pyrimidines bases of formula I-IVb is reviewed by Brown
D. “The Chemistry of Heterocyclic Compounds — The Pyrimidines “ 1962 and
Supplement 1, 1970 John Wiley and Sons, New York, by Brown D. in “Comprehensive Heterocyclic Chemistry,” Pergamon Press Vol. 7, chapter 4.09, p. 499 and by K. Unheim and T. Benneche in “Comprehensive Heterocyclic Chemistry
II’ Pergamon Press Vol. 6 chapter 6.02, p. 93.
For example, the appropriate purine base of formula I-IVa may be prepared from the corresponding purine wherein the 2, 6 or 8 position of the purine base is 67 Amended sheet 27/02/2007 substituted with a suitable leaving group such as halogen or sulphonate. Such purine ® precursors bearing leaving groups are available commercially, e.g. 6-chloropurine (Aldrich Chemical Company), 2,6-dichloropurine (Aldrich Chemical Company), 2- chloro-6-aminopurine (Aldrich Chemical Company), 8-bromoadenine (Sigma-
Aldrich Company Limited) or obtained by procedures known in the art. For example 2- and 6-chloro substituted purines can be prepared by chlorination of the corresponding 2 and 6-hydroxypurines respectively by the use of chlorinating agents such as phosphorus oxychloride (Bakuni et al. Indian J. Chem., Sect B 1984, 23, 1286; LaMontagne et al. J. Heterocycl. Chem. 1983, 20, 295) while introduction of a bromine into the 8-position of purines can be accomplished by direct bromination using brominating agents such as, for example, bromine (Mano et al, Chem Pharm
Bull 1983, 31, 3454) or N-bromosuccinimide (Kelley et al. Heterocycl. Chem. 1990, 27, 1505). The purines where the 6-substituent is alkoxy, aryloxy, SH, alkylthio, arylthio, alkylamino, cycloalkylamino, saturated cyclic amino, nitrogen linked heteroaromatic, hydroxylamino, alkoxylamino, hydrazine, alkylhydrazino may be prepared by treatment of the corresponding 6-halopurine with the appropriate alkoxides, thiols, amines, nitrogen containing heterocycles, hydroxylamines and hydrazines, (for example, Chae et al. J Med Chem, 1994, 37, 342; Niebch and
Schneider, Z. Naturforsch. B.Anorg. Chem. Org. Chem. Biochem. Biophys. Biol. 1972, 27, 675; LaMontagne et al., Heterocycl Chem 1983, 20, 295; Estep et al J Med
Chem 1995, 38, 2582). Similarly, 2-substituted purines can be prepared from the corresponding 2-halopurine, for example, purines where the 2-substituent is alkoxy, aryloxy, SH, alkythio, arylthio or NR’R* can be prepared from the corresponding 2- halopurine by treatment with alkoxides, thiols or amines (e.g. Barlin and Fenn, dust J
Chem, 1983, 36, 633; Nugiel et al., J Org Chem, 1997, 62, 201). Similarly, 8- substitued purines can be prepared from the corresponding 8-halopurines. For example purines where the 8-substituent is alkoxy, aryloxy, SH, alkythio, arylthio or
NR’R’ can be prepared by treatment of the corresponding 8-bromopurine with the appropriate alkoxides, thiols or amines (Xing et al, Tetrahedron Lett, 1990, 31, 5849;
Mano et al, Chem Pharm Bull 1983, 31, 3454). Where the 2, 6 or 8 substituent is a cyclic amine moiety the purine can be prepared from the 6-aminopurine by reaction with an appropriate dialkylating agent such as dihaloalkane. In some cases where the 68 Amended sheet 27/02/2007
6-substituent is a nitrogen containing heteroaromatic linked through the nitrogen @ atom the purine may be prepared from the 6-aminopurine by reaction with a dicarbonyl compound or a reactive derivative of this such as an acetal. For example 6-(1H-pyrrol-1-yl)-1H-purine can be prepared from a 6-chloropurine by reaction with 2,5-dimethoxytetrahydrofuran as described by Estep et al J Med Chem 1995, 38, 2582.
D. General Synthesis of 6-aryl(heteroaryl)/alkyl-substituted purine and 4- aryl(heteroaryl)/alkyl-substituted pyrimidine
Synthesis of 6-aryl(heteroaryl)/alkyl-substituted purines and 4- aryl(heteroaryl)/alkyl-substituted pyrimidines is shown in Scheme 2.
Scheme 2. [o] onto o 0
PhO OH ph—4 ¢ Tow ap 7 °7 of Nn, Ho < A 341 h&) Rm ty NH,
Pn © OP Ho oH i i ° © 346 ore 345
Pn. 0 0.” o ° ° 342 0 t ph—< Cy ® or 07 0 No HO NS 0 ° ty R-M y an J i PhO 0. Ph HO OH 8 =
Ph © OP 347 348 0 fo} 343
I
R
N ~N og
HO OH
344 69
Amended sheet 27/02/2007
PS Commercial 341 is converted to the 2’methyl-ribose derivative 342 as described in Wolfe, et al., J. Org. Chem., 1997, 62, 1754. 6-Bromopurine 2’- methylriboside (343) is prepared using the procedure for the synthesis of 6- chloropurine described in Wolfe, ef al., J. Org. Chem., 1997, 62, 1754. 6-aromatic- substituted purine 2’-methylribosides 344 are synthesized using the protocols reported by Hocek ef al., J. Med. Chem., 2000, 43, 1817 with commercially available boronic acids (R-M in Scheme 2). 6-alkyl-substituted purine 2’-methylribosides 344 are synthesized using modifications of the protocol reported by Bergstrom and
Reday, Tet. Lett., 1982, 23,4191. 6-aromatic-substituted-2-amino-purine 2’- methylribosides 345 are synthesized using modification of the protocols reported by
Lakshman ef al., Org. Lett.., 2002, 4, 1479 with commercially available boronic acids (R-B(OH); in Scheme 2). 6-alkyl- substituted-2-amino-purine 2’-methylribosides 34S are synthesized using modifications of the protocol reported by Bergstrom and
Reday, Tet. Lett., 1982, 23,4191.
In similar manner, but using the appropriate pyrimidine bases, 4- aryl(heteroaryl)/alkyl-substituted pyrimidines 348 are synthesized.
According to this protocol, the following nucleosides are prepared. #] Swwetwe | Name (J
Pa SN 9-(2’-C-methyl-pB-D-ribofuranosyl)-6- yf 's (thiophen-3-yl)-purine
HO OH
US
Np 9-(2’-C-methyl-f3-D-ribofuranosyl)-6-
SY N" NH, (thiophen-2-yl)-2-aminopurine
HO OH
70
Amended sheet 27/02/2007
N
® [, 3 & SN 9-(2’-C-methyl-B-D-ribofuranosyl)-6- “1 N (pyrrol-3-yl)-purine
HO OH
& Y 9-(2’-C-methyl-B-D-ribofuranosyl)-2- iy NPN, amino-6-phenyl-purine
HO OH
CN
& Y 9-(2’-C-methyl-B-D-ribofuranosyi)-6-(3-
Thy N cyanophenyl)-purine
HO OH
SN
= oL 9-(2’-C-methyl-B-D-ribofuranosyl)-6-
Ty nN (pyridin-3-yl)-purine
HO OH
S y . > SN 9-(2’-C-methyl-B-D-ribofuranosyl)-6-
Tie NPN, (benzo[b]thiophen-3-yl)-2-aminopurine
HO OH
HN—)
N 9-(2’-C-methyl-B-D-ribofuranosyl)-6- 74 SN “1 7 (1H-indol-5-yl)-purine
HO OH
71
Amended sheet 27/02/2007
CC 9-(2’-C-methyl-B-D-ribofuranosyl)-6- : y N .
HO SN J (naphthalen-2-yl)-purine
HO OH or
N 9-(2’-C-methyl-B-D-ribofuranosyl)-6-
AY
“1g - (dibenzofuran-4-yl)-2-aminopurine
HO OH x s & oN 9-(2’-C-methyl-B-D-ribofuranosyl)-6- “1 7 (thianthren-1-yl)-purine
HO OH
3 . ¢ > “ 9-(2’-C-methyl-B-D-ribofuranosyl)-6-
Ky N° NH, cyclopropyl-2-aminopurine
HO OH
¢ a I 9-(2’-C-methyl-B-D-ribofuranosyl)-6- “iy N (ethynyl)-purine
HO OH
Ss @
In 7-(2°-C-methyl-B-D-ribofuranosyl)-4- 2 ~N .
HO oN LZ thiophen-3-yl-7H-pyrrolo|2,3- ty d]pyrimidine
HO OH
72
Amended sheet 27/02/2007
® 7-(2’-C-methyl-B-D-ribofuranosyl)-4- z “N UT
Ho i . Ln phenyl-7H-pyrrolo[2,3-d]pyrimidin-2- 9 ylamine
HO OH
Ss 4 Z 17 Bh he 1-(2’-C-methyl-B-D-ribofuranosyl)-4-
Thy © thiophen-3-yl-1H-pyrimidin-2-one
HO OH x 1-(2’-C-methyl-f3-D-ribofuranosyi)-4- at phenyl-1H-pyrimidin-2-one
HO OH
NS 1-(2’-C-Methyl-f3-D-ribofuranosyl)-4- (oN benzo[b]thiophen-2-yl-1H-pyrimidin-2- ati one
HO OH
SN 1-(2’-C-methyl-f-D-ribofuranosyl)- 21 & ie © 4-cyclopentyl-1H-pyrimidin-2-one
HO OH
E. General Synthesis of N6-substituted adenine and
N4-substituted cytosine
Synthesis of 6-aryl(heteroaryl)/alkyl-substituted purines and 4-aryl(heteroaryl)/alkyl-substituted pyrimidines is shown in Scheme 3. 73
Amended sheet 27/02/2007
Scheme 3 te oy
HO SS [7 — he 22
HO OH
HN NH2
A
HO Ss L/ / @ ie 323 3° HO OH
Re RCS,
HO NON HO— NTN ~
HN \ hy oe,
HO OH HO OH HO ° N N 349 351 ie 324
HO OH
HO 0 N N 80 Bz — ie 325
HO OH
BzO 0OBz TU 32 Cre
Be 0 326
HO OH
C) nN - i» oy Cy Cy
BzO No HO o No HO o No
BzO 0Bz 347 HO OH 352 HO OH
NHz NH NH2 on; os; op; 4 | - y | 4 “i ; 2° J “4 *
HO OH HO OH HO OH
350 328 329 74
Amended sheet 27/02/2007
® Synthesis of 9-(2’-C-methyl- p -D-ribofuranosyl)- 6-methylthio-purine 49, 9- (2’-C-methyl- B -D-ribofuranosyl)-uridine 347, and 9-(2’-C-methyl- 8 -D- ribofuranosyl)- 6-methylthio-adenine 350 are performed as described by R. Harry-
O’kury, J. Smith, and M. Wolf J. Org. Chem. 1997, 62, 1754-1759. Methylthio- purine is oxidized to methylsulfonyl-purine using the procedure described by Y-Z.
Xu Tetrahedron, 1996, 52, 10737-10750; Y-Z. Xu, Q. Zheng, and P. Swann
Nucleosides Nucleotides 1995, 14, 929-934. For substitution of methylsulfonyl and triazolyl groups for amine, protocols similar to the protocol reported for deoxynucleosides by P.Srivastava, G.Revankar, R.Robins, and R.Rousseau J. Med.
Chem, 1981, 24, 393-398, can be used. Synthesis of 4-triazolyl-uridine and it substitution with amines can be performed as described for 2’-deoxythymidine by
Y.-Z. Xu, Q. Zheng, and P. Swann J. Org. Chem.1992, 57, 3839-3845. Bromination of purine nucleosides can be performed as described by J.Gerster et al. .J. Org.
Chem.1968, 33, 1070-1073. # | Stewe | Name
NR
- o Ras: 9-(2’-C-methyl- p -D-ribofuranosyl)- ks N8-(2-dimethylaminoethyl)-adenine
HO OH
HN NH; i” o SX 9-(2’-C-methyl-B-D-ribofuranosyl)- N° he —(2-aminoethyl)adenine
HO OH
Ne 24 “1 3 7-(2"-Crmethyl-B-Dribofuranosyl)- N®
Be N —[2-(1H-indol-3-yl)-ethyl}adenine
HO OH
& Amended sheet 27/02/2007
0 @® { Vi NH, ; S 9-(2’-C-methyl-B-D-ribofuranosyl)- 6 —
HO— NM nN? [2-aminocarbonyl-(pyrrolidine-1-yl)]- purine
HO OH
Hn NN ® © , .
HO A nro 1-(2’-C-methyl- B -D-ribofuranosyl)- ks N*-(aminocarbonylmethyl)cytidine
HO OH
(2) 2 on . 7 Oo) 1-(2’-C-methyl- B -D-ribofuranosyl)- nel N*-[(pyridin-1-yl)-methyl]cytidine
HO OH
NH, ~~ NA yA yes
Noy HON nN? 6 eT J H 9-(2’-C-methyl-f-D-ribofuranosyl)- N | ro NN? ie —[ (adenin-8-yl)-aminoethyl]adenine
HO OH
OH
OH
OH
31 oo 9-(2’-C-methyl-B-D-ribofuranosyl)- N°
N yf NZ —[(benzene-3,4,5-triol)methyl]adenine
HO OH
76
Amended sheet 27/02/2007
0} @® wi ~
N NHN 9-(2°-C-methyl-B-D-ribofuranosyl)- N°
N
2, Ne —[1-aminocarbonyl-2-(3H-indol-3-y1)- oy ethyl]adenine
HO OH
HN __
L 9-(2’-C-methyl-B-D-ribofuranosyl)- 6- 33 NNN (1,3,4,9-tetrahydro-beta-carbolin-2- ¢ 1 J
Be N yl)purine
HO OH
New
On 1-(2°-C-methyl- -D-ribofuranosyl)- 34 Oy ° N* —[1-aminocarbonyl-2-(3H-indol-3-
HO o N" "0 ke yl)-ethyl]cytosine
HO OH
F
" ; d ] NH F 1-(2’-C-methyl-B-D-ribofuranosyl)- 4-
NH
Oy (pentafluorophenyl-hydrazino)-
HO vo EET
Re pyrimidin-2-one
HO OH
OH
OH
HO 1-(2’-C-methyl-B-D-ribofuranosyl)- 4-
HO N [4-(3,4-dihydroxy-benzyl)-6,7- 37 ion ( y-benzy
Ho— no dihydroxy-3,4-dihydro-1H-isoquinolin- o y y q
RE 2-yl]-pyrimidin-2-one
HO OH
77
Amended sheet 27/02/2007
=N ® wD
SN [-(2’-C-methyl- B -D-ribofuranosyl)- 18 ~ C 3 ; yl- B yl) he N* _[ 2-(3H-indol-3-yl)-ethyl]cytosine
HO OH
NH, 7 N {D°.C- _ Dori n 39 wo f, x, 1-(2’-C-methyl- -D-ribofuranosyl)
Re N* —(2-aminoethyl)cytosine
HO OH
04 NH, ot 1-(2°-C-methyl- -D-ribofuranosyl)- “N
HO Lube N*-(aminocarbonyl-isopropyl-
Re methyl)cytidine
HO OH
NC
H in o 9-(2°-C-methyl-p-D-ribofuranosyl)- N° 53 el Ty —{[(3H-indol-3-yl)-acetic acid]-
Be N hydrazide}adenine
HO OH ry w 2 0, 9-(2°-C-methyl-B-D-ribofuranosyl)- N°®
HO oN nN? —[2-(5-fluoro-benzimidazol-1-yl)- oy ethyl]adenine
HO OH
78
Amended sheet 27/02/2007
NH, °
AQ
Ho ¢ | 9-(2’-C-methyl-B-D-ribofuranosyl)- 6 — lo} N . . he hydrazino-purine
HO OH an” Fs ae ho JN nN? 9-(2’-C-methyl-B-D-ribofuranosyl)- N he —2,2,3,3,3,-pentafluoropropyl)adenine
HO OH
CJ
NX 9-(2’-C-methyl-f3-D-ribofuranosyl)- 6- 57 IT oo
Thy N (piperidin-1-yl)purine
HO OH
H
$ A
N
HN 9-(2’-C-methyl- PB -D-ribofuranosyl)-
N NN
¢ 9, NS-[2-(1H-imidazol-4-yl)-ethyl] purine
HO OH
107 O
N e, 9-(2°-C-methyl- p -D-ribofuranosyl)- 6- le 7 (azetidin-1-yl)purine
HO OH
» 50 9-(2’-C-methyl- B -D-ribofuranosyl)- 6- le (pyrrolidin-1-yl)purine
HO OH
79
Amended sheet 27/02/2007
PS 110 0
N
74 NH al R.Dor _ vo fee (2°-C-methyl-pB-D-ribofuranosyl)
WW hypoxanthine
HO OH
112 A
HN
CTY 9-(2’-C-methyl--D-ribofuranosyl)- 6- “1 N” N- methylhydrazinopurine
HO OH
113 @
N
0 9-(2°-C-methyl-B-D-ribofuranosyl)- 6- “1 (1,2,3,4-tetrahydropyridin- 1-yl)purine
HO OH
( y 9-(2°-C-methyl-B-D-ribofuranosyl)- 6- 0, (1,2,3,4-tetrahydroisoquinolin-2- “1 > yl)purine
HO OH
Following procedures set forth above and procedures well-known in the art, as well as those described by Li ef al, 2’-C-trifluoromethyl-p-D-ribofuranosyl derivatives can be prepared.
By following the procedures set forth above, as well as procedures well known in the art, including those procedures set forth by Devos’, ef al. and
Sommadossi’ ef al., the following compounds can be made. 1-Deazapurines can be prepared and coupled to ribofuranosyl derivatives as described in by Cristalli, ef al. in J. Med. Chem. 1987, 30(9) p. 1686 or Seela, F., ef al.in Nucleosides Nucleotides, 1998, 17(4), p. 729. 80
Amended sheet 27/02/2007
R20 ® A
N
N—/ of N=
Purine nucleosides can be prepared and coupled to ribofuranosyl derivatives using methods and materials described herein.
M
N R10
G4 7 ta
N
« n={
Y
Benzimidazole nucleosides can be prepared and coupled to ribofuranosyl derivatives as described in by Sagi, G., ef al., in J. Med. Chem. 1992, 35(24), 4549.
N
"~¢ 3 5-Pyrrolopyridine Nucleosides can be prepared and coupled to ribofuranosyl derivatives as described in Tetrahedron 1976, 32, 773.
Hi
NY
$ 4-Pyrimidopyridone Sangivamycin Analogs can be prepared and coupled to ribofuranosyl derivatives as described in J. Org. Chem., 1972, 37, 3980, and J. Org.
Chem., 1977, 42, 997. 81
Amended sheet 27/02/2007
° QP o
N Ny $ 2-Pyrimidopyridone Sangivamycin Analogs can be prepared and coupled to ribofuranosyl derivatives as described in J. Org. Chem., 1977, 42, 997.
R21 0 Rr» or )
HY Sy ¢ 4-Pyrimidopyridone Sangivamycin Analogs can be prepared and coupled to ribofuranosyl derivatives as described in J. Org. Chem., 1972, 37, 3975. oO 0 M “NO
N Ny $
Pyrimidopyridine Analogs can be prepared and coupled to the sugar as described in Chem. Pharm. Bull., 1968, 16, 1076, and J. Org. Chem., 1972, 37, 3975.
Q a (R10) (R')
Or | or
NTN Ko N” NS 0 $ $
Pyrimido-tetrahydropyridines can be prepared and coupled to ribofuranosyl derivatives as described in Biorog. Khim., 1979, 5, 1369. 82
Amended sheet 27/02/2007
Q
° Ce ~ N
NSN
<
Furanopyrimidines (& tetrahydro furanopyrimidines) can be prepared and coupled to ribofuranosyl derivatives as described in J. Med. Chem., 1983, 26, 661; J.
Org. Chem., 1983, 48, 1854; and J. Med. Chem., 1985, 28, 1679.
R12 R12 0) / ? _ Rw Pa [0 2S hy Ay
Pyrazolopyrimidines can be prepared and coupled to ribofuranosyl derivatives as described in Chem. Ber., 1981, 114, 1610, and J. Med. Chem., 1983, 26, 1601.
Q R20 (R19) an oe
N » NT J
N N N
& H
Pyrolopyrimidines can be prepared and coupled to ribofuranosyl derivatives as described in Liebigs Ann. Chem., 1983, 1576.
Q R20
ARM), ZN
Ty = > NTN
NTN g
Triazolopyrimidines can be prepared and coupled to ribofuranosyl derivatives as described in J. Heterocycl. Chem., 1971, 8, 237, and J. Carbohydr. Nucleosides
Nucleotides, 1976, 3,281. 83
Amended sheet 27/02/2007
0
N-
N
¢ g
NTS
<
Pteridines can be prepared and coupled to ribofuranosyl derivatives as described in Nucleosides Nucleotides, 1989, 8, 1345, and Chem. Berich., 1974, 107, 3377.
Oo 0 J Ny
Pyridine C-nucleosides can be prepared by coupling ribofuranosyl derivatives to a variety of bases as described in Angew. Chem. Int. Ed. Engl., 1996, 35, 1968, and
Helv. Chim. Acta, 1996, 79, 702-709.
I
(R19)
Sn >
Pyrazolotriazine C-nucleosides can be prepared by coupling ribofuranosyl derivatives to a variety of bases as described in J. Heterocycl. Chem., 1976, 13, 175;
J. Heterocycl. Chem., 1976, 13, 1305; J. Heterocycl. Chem., 1980, 17, 1435; J. Org.
Chem., 1977, 42, 109.
Q
Nonny” — = —. 9-Deazapurine C-nucleosides can be prepared by coupling ribofuranosyl 84
Amended sheet 27/02/2007 derivatives to a variety of bases as described in J. Org. Chem., 1977, 42, 109; Chem. ® Ber., 1968, 101, 41; Tet. Lett., 1981, 21, 1013; J. Org. Chem., 1967, 32, 1825; J.
Heterocycl. Chem., 1978, 15, 353; Tet. Lett., 1981, 22, 25; Tet. Lett., 1986, 27, 815; and J. Med. Chem., 1990, 33, 2750.
Q
: (R10)
A Sw —
Py
Indole nucleosides can be prepared by coupling ribofuranosyl derivatives to a variety of indole bases as described in Yokoyama, M., et al., J. Chem. Soc. Perkin
Trans. I, 1996, 2145.
R20 0
N
&
Utility, Testing, and Administration
Utility
The present invention provides novel compounds possessing antiviral activity, including hepatitis C virus. The compounds of this invention inhibit HCV replication by inhibiting the enzymes involved in replication, including RNA dependent RNA polymerase. They may also inhibit other enzymes utilized in the activity or proliferation of HCV.
The compounds of the present invention can also be used as prodrug nucleosides. As such they are taken up into the cells and can be intracellularly phosphorylated by kinases to the triphosphate and are then inhibitors of the polymerase (NS5b) and/or act as chain-terminators.
Compounds of this invention maybe used alone or in combination with other compounds to treat viruses. 85
Amended sheet 27/02/2007
Administration and Pharmaceutical Composition ® In general, the compounds of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of the compound of this invention, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors. The drug can be administered more than once a day, preferably once or twice a day.
Therapeutically effective amounts of compounds of Formula Ia, Ib, Ic, II, IIA,
I1I, or IV may range from approximately 0.05 to 50 mg per kilogram body weight of the recipient per day; preferably about 0.01-25 mg/kg/day, more preferably from about 0.5 to 10 mg/kg/day. Thus, for administration to a 70 kg person, the dosage range would most preferably be about 35-70 mg per day.
In general, compounds of this invention will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen that can be adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions. Another preferred manner for administering compounds of this invention is inhalation. This is an effective method for delivering a therapeutic agent directly to the respiratory tract, in particular for the treatment of diseases such as asthma and similar or related respiratory tract disorders (see U. S. Patent 5,607,915).
The choice of formulation depends on various factors such as the mode of drug administration and bioavailability of the drug substance. For delivery via inhalation the compound can be formulated as liquid solution, suspensions, aerosol 86 Amended sheet 27/02/2007 propellants or dry powder and loaded into a suitable dispenser for administration. ® There are several types of pharmaceutical inhalation devices-nebulizer inhalers, metered dose inhalers (MDI) and dry powder inhalers (DPI). Nebulizer devices produce a stream of high velocity air that causes the therapeutic agents (which are formulated in a liquid form) to spray as a mist that is carried into the patient’s respiratory tract. MDI’s typically are formulation packaged with a compressed gas.
Upon actuation, the device discharges a measured amount of therapeutic agent by compressed gas, thus affording a reliable method of administering a set amount of agent. DPI dispenses therapeutic agents in the form of a free flowing powder that can be dispersed in the patient’s inspiratory air-stream during breathing by the device. In order to achieve a free flowing powder, the therapeutic agent is formulated with an excipient such as lactose. A measured amount of the therapeutic agent is stored in a capsule form and is dispensed with each actuation.
Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example,
U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
The compositions are comprised of in general, a compound of Formula Ia, Ib,
Ic, 11, IIA, III, or IV in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of Formula Ia, Ib, Ic, II, TTA,
III, or IV. Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art. 87 Amended sheet 27/02/2007
Solid pharmaceutical excipients include starch, cellulose, talc, glucose, ® lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.
Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
Other suitable pharmaceutical excipients and their formulations are described in
Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing
Company, 18th ed., 1990).
The amount of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (Wt%) basis, from about 0.01-99.99 wt% of a compound of Formula
Ia, Ib, Ic, II, ITA, 111, or IV based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80 wt%. Representative pharmaceutical formulations containing a compound of Formula Ia, Ib, Ic, II, TIA, III, or IV are described below.
In the examples below, the following abbreviations have the following meanings. lf an abbreviation is not defined, it has its generally accepted meaning.
DS
EC SA
= CT 88 Amended sheet 27/02/2007
Boc Py N-Boc-4-amino-1-methyl pyrrole-2-carboxylic o [| [e—
EE
BeTin |=[Nes Anno eT Ao
Boc-5-Ain-HBA-AMPS N-Boc-5-Amino-Indole-2-Carboxylic Acid (p-
I i og
Boc-Py-HBA-AMPS N-Boc-4-Amino-1-Methyl Pyrrole-2-Carboxylic
Acid (p-Hydroxy benzamide methyl polystyrene)ester
BOP Benzotriazol-1-yloxy- tris(dimethylamino)phosphonium mmm—
CL
I Li i
IC LL
IC LE
EE So SR
EC
EE So
Eo Co
Fo LL
Eo
Ee GO LC
EC Ec
Ee Po
EL Lr
Ec rr
ES SO
Ea
Ee eC
Amended sheet 27/02/2007 o [FT [ [owes
Eo SO
Ec
EO ero SR
CC
EE
CE
EE GC = RE
EE LE
Fee [Terman pins
EE
EC
CL
AAS |= phan ees
HBTU O-Benzotriazol-1yl-N,N,N’,N’-
IR onion
WE | omar Ts sry
FE Le
ER RL Te
EL i
EE SA
EEE
EL
Ec
EE we fees
EC
EE A
EC
= Amended sheet 27/02/2007
® MMT monomethoxytrytil (p-anisyldiphenylmethyl)
I Hl Fe
EE OL
EE a
EL Le
ER LE
EL Te
EC iL
Npc(Et) 4-nitro-1-ethyl-1H-pyrrole-2-carboxylic acid em
Npc(Me) 4-nitro-1-methyl-1H-pyrrole-2-carboxylic acid
RA
Npc(Pr) 4-nitro-1-propyl-1H-pyrrole-2-carboxylic acid
RR I
EE oe B
FC [LE
CE le
Py 4-amino-1-methyl-1H-pyrrole-2-carboxylic acid
RE
Br fees
Pzl-Gu-(Boc), N,N ’-Bis(tert-butoxycarbonyl)-1 H-pyrazole-1- i
EE i
EC
EC fee
EE
EE i CCE
EE i A
REE ol Amended sheet 27/02/2007 i
TE fee
ELC SN Lr
EO Le [eee
WE [mee
EC
A wo eee
FE Cl
EF cS
EL GO i
CL
EL
FL [1
EE fee
OVE [perv en
In reporting NMR data, chemical shifts are given in ppm and coupling constants (J) given in Hertz (Hz). All melting points are uncorrected.
In the following examples and procedures, the starting materials and reagents are commercially available from any one of Aldrich, Lancaster, Sigma, Specs, TCI,
Maybridge Frontier Scientific and Bachem. The term "Aldrich" indicates that the compound or reagent used in the procedure is commercially available from Aldrich
Chemical Company, Inc., Milwaukee, WI 53233 USA; the term "Lancaster" indicates that the compound or reagent is commercially available from Lancaster Synthesis,
Inc., NH 03087 USA; the term "Sigma" indicates that the compound or reagent is commercially available from Sigma, St. Louis MO 63178 USA; the term "Maybridge" indicates that the compound or reagent is commercially available from
Maybridge Chemical Co. Trevillett, Tintagel, Cornwall PL34 OHW United 72 Amended sheet 27/02/2007
Kingdom; and the term "TCI" indicates that the compound or reagent is commercially ® available from TCI America, Portland OR 97203; the term "Frontier Scientific" indicates that the compound or reagent is commercially available from Frontier
Scientific, Utah, USA; the term "Specs" indicates that the compound or reagent is commercially available from Netherlands; and "Bachem" indicates that the compound or reagent is commercially available from Bachem, Torrance, California,
USA.
Set forth in the examples below are compounds and intermiediates useful for making compounds of the present invention.
Example 1
Synthesis of 9-(2°-C-methyl- B -D-ribofuranosyl)- 6-bromopurine (41) 9-(2’-C-methyl- B -D-ribofuranosyl)- 6-bromopurine (41) can be synthesized utilizing the general procedure described in R. Harry-O’kuru, J. Smith, and M. Wolf
J. Org. Chem. 1997, 62, 1754-1759.
Example 2
Synthesis of 9-(2°-C-methyl--D-ribofuranosyl)-6-(thiophen-3-yl)-purine (1)
Toluene (10 mL) is added to an argon-purged flask containing 9-(2’-C- methyl- B -D-ribofuranosyl)- 6-bromopurine (41) (1 mmol), K,CO3 (200 mg, 1.5 mmol), 3-thiopheneboronic acid (1.5 mmol) and Pd(PPhs)s (59 mg, 0.05 mmol) and the mixture is stirred under argon at 100°C for 8 h. After cooling to ambient temperature the mixture is evaporated in vacuo and the residue is chromatographed on a silica gel column. The residue is then taken up into 10 mL NHj3 saturated MeOH and reacted at 55°C for 12 hours in a sealed tube. The reaction was cooled and concentrated in vacuo. The product was isolated by column chromatography on silica gel (chloroform/methanol/ammonia 9:1:0.5 v/v/v).
Example 3
Synthesis of 9-(2’-C-methyl- B -D-ribofuranosyl)- N*-isobutyryl-guanosine (42) 9-(2’-C-methyl- p -D-ribofuranosyl)- N’-isobutyryl-guanosine (42) is 7 Amended sheet 27/02/2007 synthesized utilizing the general procedure described in R. Harry-O’kuru, J. Smith, ® and M. Wolf J. Org. Chem. 1997, 62, 1754-1759 and is isolated by HPLC.
Example 4
Synthesis of 9-(2°-C-methyl- B -D-ribofuranosyl)-2-amino-6-phenylpurine (4) 9-(2’-C-methyl- B -D-ribofuranosyl)- N*-isobutyryl-guanosine (42) (1 mmol) is dissolved in dichloromethane (10 mL) under argon and 2,6-di-tert-butyl-4- methylpyridine (3 mmol) is added. The solution is cooled to 0°C and trifluoromethanesulfonic anhydride (3 mmol) is added and the reaction is allowed to warm to ambient temperature. After 12 hours the reaction is concentrated in vacuo and chromatographed on silica gel (ethyl acetate/dichoromethane). The product is dissolved in toluene (10 mL) and then K;COj3 (200 mg, 1.5 mmol), phenylboronic acid (1.5 mmol) and Pd(PPh3)4 (59 mg, 0.05 mmol) are added and the mixture is stirred under argon at 100°C for 8 h. After cooling to ambient temperature the mixture is evaporated in vacuo and the residue is chromatographed on a silica gel column. The residue is then taken up into 10 mL NHj3 saturated MeOH and reacted at 55°C for 12 hours in a sealed tube. The reaction is cooled and concentrated in vacuo.
The product is isolated by column chromatography on silica gel (chloroform/methanol/ammonia 9:1:0.5 v/v/v).
Example 5
Synthesis of 9-(2’-C-methyl- 3 -D-ribofuranosyl)-uracil (43) 9-(2’-C-methyl- -D-ribofuranosyl)-uracil (43) is synthesized as described in
R. Harry-O’kuru, J. Smith, and M. Wolf J. Org. Chem. 1997, 62, 1754-1759.
Example 6
Synthesis of 1-(2’-C-methyl-B-D-ribofuranosyl)-4-thiophen- 3-yl-1H-pyrimidin-2-one (17) 9-(2’-C-methyl- p -D-ribofuranosyl)-uracil (43) (1 mmol) is dissolved in dichloromethane (10 mL) under argon and 2,6-di-tert-butyl-4-methylpyridine (3 mmol) is added. The solution is cooled to 0°C and trifluoromethanecsulfonic 4 Amended sheet 27/02/2007 anhydride (3 mmol) is added and the reaction is allowed to warm to ambient ® temperature. After 12 hours the reaction is concentrated in vacuo and chromatographed on silica gel (ethyl acetate/dichoromethane). The product is dissolved in toluene (10 mL) and then K>CO5 (200 mg, 1.5 mmol), 3- thiopheneboronic acid (1.5 mmol) and Pd(PPh;)4 (59 mg, 0.05 mmol) are added and the mixture is stirred under argon at 100 °C for 8 h. After cooling to ambient temperature the mixture is evaporated in vacuo and the residue is chromatographed on a silica gel column. The residue is taken up into 10 mL NHj saturated MeOH and is reacted at 55°C for 12 hours in a sealed tube. The reaction is cooled and concentrated in vacuo. The product is isolated by column chromatography on silica gel (chloroform/methanol/ammonia 9:1:0.5 v/v/v).
Example 7
Synthesis of 1-(2’-C-methyl-B-D-ribofuranosyl)-4-cyclopentyl- 1 H-pyrimidin-2-one ( 21) 9-(2°-C-methyl- B -D-ribofuranosyl)-uracil (43) (1 mmol) is dissolved in dichloromethane (10 mL) under argon and 2,6-di-tert-butyl-4-methylpyridine (3 mmol) is added. The solution is cooled to 0°C and trifluoromethanesulfonic anhydride (3 mmol) is added and the reaction is allowed to warm to ambient temperature. After 12 hours the reaction is concentrated in vacuo and chromatographed on silica gel (ethyl acetate/dichoromethane). The product is dissolved in anhydrous THF (10 mL) and Pd(PPhs)4 (59 mg, 0.05 mmol) is added under Ar atmosphere. Cyclopentylzinc bromide (1.5 mmol, 0.5 M in THF) is then added and the reaction stirred at ambient temperature for 18 hours. The mixture is evaporated in vacuo and the residue is chromatographed on a silica gel column. The residue is taken up into 10 mL NH; saturated MeOH and reacted at 55°C for 12 hours in a sealed tube. The reaction is cooled and concentrated in vacuo. The product is isolated by column chromatography on silica gel (chloroform/methanol/ammonia 9:1:0.5 v/v/v).
Example 8
Synthesis of 9-(2°-C-methyl- B -D-ribofuranosyl)- 6-methylthio-purine (49) % Amended sheet 27/02/2007
® 9-(2’-C-methyl- B -D-ribofuranosyl)- 6-methylthio-purine (49) is synthesized as described in R. Harry-O’kuru, J. Smith, and M. Wolf J. Org. Chem. 1997, 62, 1754-1759.
Example 10
Synthesis of 9-(2°-C-methyl- $ -D-ribofuranosyl)- 6-[2-(1H-imidazol-4-yl)- ethyljpurine (106)
Compound 106 was synthesized as described herein from histamine.
MS 361.45 (M+H)
H'-NMR (DMSO0-d6): 0.80 (s, 3H, 2’-CH3), 3.25-3.45 (m, 4H, methylene), 3.53-4.05 (m, 7H, sugar), 5.99 (s, 1H, 1’-H), 7.48 and 9.09 (s, 1H, purine), 8.35 and 8.65 (bs, 0.7H, imidazole)
Example 11
Synthesis of 9-(2’-C-methyl-B-D-ribofuranosyl)-N® —(2-aminoethyl)adenine (23) 9-(2’-C-methyl-B-D-ribofuranosyl)-6 —(methylsulfonyl)purine (1 mmol) is dissolved in pyridine (5 mL), ethylenediamine (5 mM) is added and the reaction mixture is kept overnight at room temperature. The solvent is evaporated; the product (23) is isolated by column chromatography on silica gel (chloroform/methanol/ ammonia 9:1:0.5, v/v/v).
Example 12
Synthesis of 9-(2’-C-methyl-B-D-ribofuranosyl)-N°-[2-(1H-indol-3-yl)- ethylladenine (24)
Compound 24 was synthesized as described herein from tryptamine.
MS 410.38 (M+H)
H'-NMR (DMSO0-d6): 0.76 (s, 3H, 2°-CH3), 2.60-4.10 (m, sugar and methylene), 5.98 (s, 1H, 1’-H), 6.80 (d, 1H, indole), 7.18 (m, 4H, indole), 8.35 and 8.68 (s, 1H, purine), 9.02 (s, 1H, NH).
Example 13
Synthesis of 9-(2°-C-methyl- -D-ribofuranosyl)- 6-[2-aminocarbonyl- 26 Amended sheet 27/02/2007
(pyrrolidin-1-yl)}-purine (25) ® Compound 25 was synthesized as described herein from L-proline amide.
MS 380.35 (M+H)
H'-NMR (DMSO0-d6): 0.86 (s, 3H, 2°-CH3), 2.25-3.95 (m, 4H, pyrrolidine), 3.10-4.10 (m, sugar and pyrrolidine), 5.98 (s, 1H, 1°-H), 8.35 and 8.68 (s, 1H, purine), 9.25 (s, 1H, amide).
Example 14
Synthesis of 1-(2°,3°.5°-Tri-O-benzoyl -2°-C-methyl-B-D-ribofuranosyl)- uracil (47) 1-(2°,3°,5’-Tri-O-benzoyl-2’-C-methyl-B-D-ribofuranosyl)-uracil ( 47) is synthesized as described in R. Harry-O’kuru, J. Smith, and M. Wolf J. Org. Chem. 1997, 62, 1754-1759.
Example 15
Synthesis of 1-(2°.3°.5°-Tri-O-benzoyl-2’-C-methyl-B-D-ribofuranosyl)-4- (1.2.4-triazol-1-yl) uracil (52) 1,2,4-Triazo! (60 mmol) is suspended in dry acetonitrile (70 mL) at 0°C.
Phosphorous oxychloride (15 mM) is slowly added with rapid stirring followed by drop wise addition of triethylamine (50 mmol). The reaction mixture is stirred for 30 min at 0°C and than nucleoside (47) (15 mmol) is added. In 1 hour the reaction is quenched with 50 mL of saturated solution of sodium bicarbonate, The product is extracted with 50 mL of chloroform. Organic extract is washed with 5% sodium bicarbonate, water, dried over magnesium sulphate and evaporated. The product is isolated by column chromatography on silica gel (toluene/ethyl acetate).
Example 16
Synthesis of 1-(2°-C-methyl- B -D-ribofuranosyl)-N"- (aminocarbonylmethyl)cytidine (26)
Nucleoside (52) (1 mmol) is dissolved in 95% pyridine (5 mL), glycine amide (5 mM) is added and the reaction mixture is kept for 16 hours at 55°C. The solvent is evaporated. The product (26) is isolated by column chromatography on silica gel 77 Amended sheet 27/02/2007
® (chloroform/methanol/ammonia 9:1:0.5 v/v/v).
Example 17
Synthesis of 1-(2’-C-methyl- 8 -D-ribofuranosyl)- :
N*(pyridin-1-yl)methyl)cytidine (27)
Nucleoside (52) (1 mmol) is dissolved in 95% pyridine (5 mL), pyridin-1-yl- methylamine (5 mM) is added and the reaction mixture is kept for 16 hours at 55°C.
The solvent is evaporated. The product (27) is isolated by column chromatography on silica gel (chloroform/methanol/ammonia 9:1:0.5 v/v/v).
Example 18
Synthesis of 2°-C-methyladenosine (50) 2’-C-methyladenosine (50) is prepared as described in R. Harry-O’kuru, J.
Smith, and M. Wolf J. Org. Chem. 1997, 62, 1754-1759.
Example 19
Synthesis of 2’-C-methyl-8-bromoadenosine (28)
Bromine (2 mL) is added to S50 mL of water and stirred vigorously at room temperature for 3 min. Nucleoside (50) (5g) is suspended in 30 mL of water and Br,- water is added by aliquots at such a rate that yellow color of the reaction mixture disappeared between each addition. The total amount of Br,-water is 45 mL. The solid is collected by filtration and washed carefully with iced water up to pH 5.5. The residue is recrystallized from hot water to yield 60% of the target product.
Example 21
Synthesis of 5-(2’-C-methyl-f3-D-ribofuranosyl)-S H- pyrrolo[3.2-c]pyridin-4-ylamine (80)
The title compound can be prepared by methods similar to those set forth by
Ducrocq® on page 779 to 780.
Example 22
Synthesis of 4-amino-8-(2°-C-methyl-B-D-ribofuranosyl)-5-oxo- ’8 Amended sheet 27/02/2007
5.8-dihydro-pyrido[2.3-d]pyrimidine-6-carboxylic acid amide (81) ® The title compound can be prepared by methods similar to those set forth by
Rizkalla’ on page 3985.
Example 23
Synthesis of 2.4-diamino-8-(2’-C-methyl-B-D-ribofuranosyl)-5-0x0-5.8- dihydro-pyrido[2.3-d]pyrimidine-6-carboxylic acid amide (82)
The title compound can be prepared by methods similar to those set forth by
Anderson? page 999.
Example 24
Synthesis of 4-amino-8-(2°-C-methyl-B-D-ribofuranosyl)-7-oxo- 7.8-dihydro-pyrido[2.3-d]pyrimidine-5-carboxylic acid amide (83)
The title compound can be prepared by methods similar to those set forth by
Anderson® page 1000.
Example 25
Synthesis of 2.4-diamino-8-(2’-C-methyl-B-D-ribofuranosyl)-7- 0x0-7.8-dihydro-pyrido[2.3-d]pyrimidine-5-carboxylic acid amide (84)
The title compound can be prepared by methods similar to those set forth by
Anderson® page 1000.
Example 26
Synthesis of 8-(2°-C-methyl-B-D-ribofuranosyl)-2-methylsulfanyl- 4,5-diox0-3.4,5.8-tctrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid amide (85)
Step 1. Synthesis of 2-methylsulfanyl-4.5-dioxo-3.4.5.8-tetrahydro-pyrido[2.3- d]pyrimidine-6-carboxylic acid ethyl ester 4,5-dioxo-3,4,5,8-tetrahydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester was synthesized as described in B.H.Rizkalla and A.D.Broom, J Org.Chem. 1972, 37(25), 3980-3985.
Step 2. Synthesis of 8~(2°, 3°, 5°-tris-benzoyloxy-2’-C-methyl-8-D-ribofuranosyl)-2- » Amended sheet 27/02/2007 methylsulfanyl-4.5-dioxo-3.4.5.8-tetrahydro-pyrido[2.3-d]pyrimidine-6-carboxylic ® acid ethyl ester
To a suspension of the product from Step 1 above (0.2g, 0.71mmol) in dry acetonitrile (3.5 mL), BSA (0.385 mL, 1.56 mmol) was added and the mixture refluxed under argon for 30min. The resulting solution was cooled to room temperature and 1,2,3,5-tetra-O-benzoyl-2’-C-methyl B-D-ribofuranose (0.32g, 0.55mmol) in dry acetonitrile was added followed immediately by TMSOTT (0.513 mL, 2.84 mmol). The resulting reaction mixture was heated to reflux for 2 hours.
The reaction was allowed to cool to room temperature then was concentrated in vacuo to an oily residue. The oily residue was taken up in EtOAc and washed 1X with saturated NaHCO; and the aqueous layer was re-extracted 2X with EtOAc. The organic fractions were combined, washed with H,O, brine, and dried over Na;SO4 and concentrated in vacuo. The crude reaction was purified by column chromatography on silica gel using 10% methanol in methylene chloride for elution.
The appropriate fractions were pooled, evaporated, and foamed from methylene chloride to get 0.406g (100%) of the title compound.
Step 3. Synthesis of 8-(2°-C-methyl-B-D-ribofuranosyl)-2-methylsulfanyl-4,5-dioxo- 3.4.5.8-tetrahydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid amide.
The product from Step 2 above (0.2g, 0.270mmol) was dissolved in 40mLs liquid ammonia and stirred at room temperature for 48 hours. The liquid ammonia was allowed to evaporate and the resulting yellow oily residue was purified by HPLC 0-20% Buffer B over 30min at a flow rate of 10mLs/min. Buffer A — 0.1% triethylammonium acetate in water, Buffer B-0.1% triethylammonium acetate in
CH;3;CN. Pooled fractions containing nucleoside and evaporated in vacuo and dried by co-evaporation with absolute ethanol to yield 27mg (25%) of the desired nucleoside.
MS: 397.13 (M-H).
H'-NMR (DMSO-d6): 0.8 (s, 3H, 2’-CHs), 2.5 (s, 3H, -CH3), 3.0-4.0 (m, 4H, sugar), 5.0-5.5 (m, 3H, -OH), 6.7 (s, 1H, 1°-H), 7.4 (s, 1H, -Ar), 8.8 and 9.2 (s, 2H, -NHy). 100 Amended sheet 27/02/2007
® Example 27
Synthesis of 8-(2°-C-methyl-B-D-ribofuranosyl)-8 H- pyrido[2.3-d]pyrimidine-2.4-dione (86)
The title compound can be prepared by methods similar to those set forth by
Rizkalla’ on page 3979.
Example 28
Synthesis of 1-(2°-C-methyl-B-D-ribofuranosyl)-1H- pyrido[2.3-d]pyrimidine-2.4-dione (87)
The title compound can be prepared by methods similar to those set forth by
Rizkalla® on page 3979.
Example 29
Synthesis of 8-(2°-C-methyl-B-D-ribofuranosyl)-4- methylsulfanyl-5.6.7.8-tetrahydro-pyrido[2.3-d]pyrimidine (88)
The title compound can be prepared by methods similar to those set forth in
Biorog. Khim., 1979, 5, 1369.
Example 30
Synthesis of 3-(2’-C-methyl-B-D-ribofuranosyl)-6-methyl- 3.7a-dihydro-1H-furo[2,3-d]pyrimidin-2-one (89)
The title compound can be prepared by methods similar to those set forth in
De Clercq'? page 666.
Example 31
Synthesis of 3-(2°-C-methyl-8-D-ribofuranosyl)- 3.5,6.7a-tetrahydro-1H-furo[2.3-d]pyrimidin-2-one (90)
The title compound can be prepared by making appropriate modifications to the methods set forth by Grieng]" on page 1680.
Example 33
Synthesis of 7-(2’-C-methyl-B-D-ribofuranosyl)-4-methylsulfanyl-7 H- 101
Amended sheet 27/02/2007
Ie pyrrolo[2.3-d]pyrimidine (92) ® The title compound can be prepared by methods similar to those set forth by
Seela'” page 1585.
Example 34
Synthesis of 1-(2°-C-methyl-B-D-ribofuranosyl)-4-methylsulfanyl-1H- pyrrolo[2.3-d]pyrimidine (93)
The title compound can be prepared by methods similar to those set forth by
Seela'” page 1585.
Example 35
Synthesis of 3-(2’-C-methyl-B8-D-ribofuranosyl)-3H- [1,2.4]triazolo[1.5-a]pyrimidin-7-one (94)
The title compound can be prepared by methods similar to those set forth in
Winkley'® page 239.
Example 36
Synthesis of 3-methyl-8-(2’-C-methyl--D-ribofuranosyl)-2- methylsulfanyl-3H.8H-pteridine-4.7-dione (95)
The title compound can be prepared by methods similar to those set forth by
Hawkin®®, et al. page 2875.
Example 37
Synthesis of 5-(2’-C-methyl-B-D-ribofuranosyl)pyridin-2-ylamine (96)
The title compound can be prepared by coupling the alternative the sugar f, prepared as described in Scheme 1, to the base prepared by methods similar to those described previously 2
Example 38
Synthesis of 5-(2’-C-methyl-B-D-ribofuranosyl)-1 H-pyridin-2-one (97)
The title compound can be prepared by coupling the alternative sugar f, prepared as described in Scheme 1, to the base prepared by methods similar to those 102 Amended sheet 27/02/2007
® described previously.”>?
Example 39
Synthesis of 8-(2’-C-methyl-B-D-ribofuranosyl)-pyrazolo[1,5-a] [1.3.5]triazin-4-ylamine (98)
The title compound can be prepared by coupling the alternative sugar f, prepared as described in Scheme 1, to the base prepared by methods similar to those described by Tam’, ef al. on page 1307. Other pyrazolotrazine C-nucleosides, for example compounds 99 and 100, may be prepared using this sugar (f) and other techniques well known in the art.*?’
Example 41
Synthesis of 9-(2’-C-trifluoromethyl-B-D-ribofuranosyl)-
N°-(2-aminoethyl)adenine (62)
The title compound can be prepared by methods similar to those set forth by
Li*, ef al. and methods described herein. Trifluoromethylated ribofuranosyl derivates maybe coupled to a variety of bases, for example compounds 63, 64, 66 and 67, may be prepared by techniques described herein as well as methods well known in the art.
Example 42
Synthesis of 1-(2°-C-ethenyl-B-D-ribofuranosyl)-1H-benzimidazole (73)
The title compound can be prepared by methods similar to those set forth by
Sagi’ 8 et al. and methods described herein. Ethenylated ribofuranosyl derivates maybe coupled to a variety of bases, for example compounds 68-70, may be prepared by techniques described herein as well as methods well known in the art.
Examplc 43
Synthesis of 1-(2°-C-ethynyl-B-D-ribofuranosyl)-1 H-benzimidazole (79)
The title compound can be prepared by methods similar to those set forth by
Sagi’?, et al. and methods described herein. Ethynylated ribofuranosyl derivates maybe coupled to a variety of bases, for example compounds 74-76, may be prepared 103 Amended sheet 27/02/2007
® by techniques described herein as well as methods well known in the art.
Example 44
Synthesis of 1-(2°-C-methyl-B-D-ribofuranosyl)-4-nitroindole (104)
The title compound can be prepared by methods similar to those set forth in
Yokoyama®, ef al. Other Indole nucleosides can be prepared by coupling ribofuranosyl derivatives to a variety of indole, for example compounds 105, maybe prepared by techniques described herein as well as methods well known in the art.
Example 45
Synthesis of 9-(2’-C-methyl- B -D-ribofuranosyl)- 6-(azetidin-1-yl)purine (107)
Compound 107 was synthesized as described herein from azetidine.
MS 323.32 (M+H)
H'-NMR (DMSO-d6): 0.76 (s, 3H, 2°-CHs), 3.25-3.45 (m, 4H, methylene), 3.10-4.10 (m, sugar and azetidine), 5.98 (s, 1H, 1’-H), 8.35 and 8.68 (s, 1H, purine).
Example 46
Synthesis of 9-(2’-C-methyl- $ -D-ribofuranosyl)- 6-(pyrrolidin-1-yl)purine (108)
Compound 108 was synthesized as described herein from pyrrolidine.
MS 336.32 (M+H)
H'-NMR (DMSO0-d6): 0.77 (s, 3H, 2’-CH3), 2.00 (m, 4H, pyrrolidine), 3.43- 4.14 (m, sugar and pyrrolidine), 5.98 (s, 1H, 1°-H), 8.36 and 8.72 (s, 1H, purine).
Example 47
Synthesis of 9-(2’-C-methyl- B -D-ribofuranosyl)- 6-(piperidin-1-yl)purine (57)
Compound 57 was synthesized as described herein from pyrrolidine.
MS 350.37 (M+H)
H'-NMR (DMSO0-d6): 0.78 (s, 3H, 2°-CH3), 1.62 (m, 6H, piperidine), 3.43- 3.88 (m, sugar and piperidine), 4.01-4.02 (d, 1H, 3’-H) 5.97 (s, 1H, 1’-H), 8.28 and 8.58 (s, 1H, purine). 104 Amended sheet 27/02/2007
Example 48 ® Synthesis of 9-(2’-C-methyl-B-D-ribofuranosyl)- 6 —(hydroxylamino)purine (109) and 9-(2°-C-methyl-B-D-ribofuranosyl)- hypoxanthine (110) 9-(2'-C-methyl-B-D-ribofuranosyl)-6-(methylsulfonyl)purine (0.2 mmol) was dissolved in 3 mL of dry ethanol, solution of hydroxylamine (prepared as described by P.K.Chang, J. Med.Chem., 1965, 8, 884) was added (2 mM) and the mixture was refluxed for 1 h and than concentrated in vavuo. The residue was dissolved in DMF (5 mL) and purified by HPLC 20-100% B in 30 min, flow 10 mL/min. A-0.2% triethylammonium acetate in water, B-0.2% triethylammonium acetate in CH3CN.
The fractions contained the mixture of protected nucleosides 109 and 110 were evaporated, dissolved in MeOH, treated with HCl/MeOH for 5 min at 0°C and the mixture of nucleosides 109 and 110 (3:1) was precipitated with ether. The mixture was separated by HPLC, 0-20% B in 30 min, buffers as described above.
Corresponding fractions were combined, evaporated, co-evaporated with water (3 x 10 mL), dissolved in methanol (1 mL) and precipitated with ether (35 mL) to yield white solid. 9-(2’-C-methyl-B-D-ribofuranosyl)- N° —(hydroxylamino)purine (109)
MS: 283.19 (M+H),
Amax 261.5nm, )
H'-NMR (DMSO-d6): 0.68 (s, 3H, 2’-CH3), 3.81-4.04 (m, 2H, 5’-H) 4.07 (1, 1H, 4-H), 4.17-4.20 (d, 3°-H), 6.06 (s, 1H, 1°-H), 8.06 and 8.53 (s, 1H, purine). 9-(2°-C-methyl- -D-ribofuranosyl)- hypoxanthine (110).
MS: 298.38 (M+H),
Amax 249.5 nm,
H'-NMR (DMSO0-d6): 1.09 (s, 3H, 2°-CH3), 3.85-4.24 (m, 3H, sugar), 6.16 (s, 1H, 1’-H), 8.21 and 8.62 (s, 1H, hypoxanthine).
Example 49
Synthesis of 9-(2’-C-methyl- 3 -D-ribofuranosyl)- 6-methoxyaminopurine (111)
Compound 111 was synthesized as described herein from methoxyamine. 105 Amended sheet 27/02/2007
MS 312.41 (M+H); ® H'-NMR (DMSO0-d6): 0.91 (s, 3H, 2°-CHj), 3.82-4.04 (m, 7H, sugar), 3.95 (s,
O- CH3), 6.01 (s, 1H, 1°-H), 8.22 and 8.88 (s, 1H, adenine).
Example 50
Synthesis of 9-(2’-C-methyl-B-D-ribofuranosyl)- 6-hydrazinopurine (55)
Nucleoside 55 was synthesized as described herein from hydrazine.
MS 297.31 (M+H)
H'-NMR (DMSO0-d6): 0.80 (s, 3H, 2°-CHs), 3.80-4.00 (m, 7H, sugar), 6.02 (s, 1H, 1°-H), 8.47 and 8.77 (s, 1H, purine).
Example 51
Synthesis of 9-(2°-C-methyl-B-D-ribofuranosyl)- 6-N-methylhydrazinopurine (112)
Nucleoside 112 was synthesized as described herein from hydrazine.
MS 313.72 (M+H)
H'-NMR (DMSO-d6): 0.68 (s, 3H, 2°-CH3), 3.80-4.00 (m, 7H, sugar), 3.88 (s,
N- CH3), 5.90 (s, 1H, 1’-H), 7.68 and 8.21 (s, 1H, purine).
Example 52
Synthesis of 9-(2°-C-methyl- 8 -D-ribofuranosyl)- 6-(1.2.3.4-tetrahydropyridin-1-yl) purine (113)
Compound 113 was synthesized as described herein from 3,6- dihydropyridine.
MS 348.32 (M+H)
H'-NMR (DMSO-d6): 0.88 (s, 3H, 2°-CH3), 3.10-3.40 (m, 6H, CH2- tetrahydropyridine), 3.80-4.00 (m, 7H, sugar), 5.80-5.98 (m, 2H, CH- tetrahydropyridine), 6.01 (s, 1H, 1°-H), 8.23 and 8.48 (s, 1H, purine).
Example 53
Synthesis of 9-(2°-C-methyl- 8 -D-ribofuranosyl)- 6-(1.2.3.4-tetrahydroisoquinolin-2- yl)purine (114) 106 Amended sheet 27/02/2007
Compound 114 was synthesized as described herein from 3,4- ® dihydroisoquinoline.
MS 398.53 (M+H)
H'-NMR (DMSO0-d6): 0.88 (s, 3H, 2°-CH3), 2.25-2.31 and 2.90-3.00 (m, 2H, methylene), 3.10-3.40 (m, 6H, CH,-tetrahydropyridine), 3.80-4.00 (m, 4H, sugar), 5.20-5.35 (m, 3H, OH-sugar), 6.01 (s, 1H, 1°-H), 7.16-7.25 (m, 4H, benzene), 8.27 and 8.53 (s, 1H, purine).
Example 54
Preparation of 9-(2°-C-methyl- -D-ribofuranosyl)- 6-(1.3.4.9-tetrahydro-beta- carbolin-2-yl)purine (33)
Compound 33 was synthesized as described herein from 1,3,4,9-tetrahydro- beta-carboline.
MS 437.43 (M+H)
H'-NMR (DMSO-d6): 0.89 (s, 3H, 2’-CHs), 2.98 (m, 2H, methylene), 3.40- 4.00 (m, sugar and methylene of tetrahydopyridine), 4.05 (d, 3°-H), 6.05 (s, 1H, 1°-
H), 6.90-7.05 (m, 2H, aromatic), 7.29-7.40 (m, 2H, aromatic), 8.32 and 8.65 (s, 1H, purine), 10.99 (s, 1H, NH).
Example 55
Synthesis of 7-(2’-C-methyl-B-D-ribofuranosyl)- 4- hydroxylamino-pyrrolo[2,3- d]pyrimidine (117)
Step 1. Synthesis of 7-(2’-C-methyl-B-D-ribofuranosyl)- 4- chloro-pyrrolo[2,3- dlpyrimidine (141) was prepared as described in WO 02/057287, p 27-30.
Step 2. 7-(2’-C-methyl--D-ribofuranosyl)- 4- hydroxylamino-pyrrolo[2,3- d]pyrimidine (117).
Nucleoside 141 (300 mg, 1 mmol) was dissolved in dry ethanol (10 mL), solution of hydroxylamine (prepared as described by P.K.Chang, J. Med.Chem., 1965, 8, 884) was added (10 mM) and the mixture was refluxed for 1 h and than concentrated in vavuo. The residue was purified by HPLC 0-30% B in 30 min, flow 10 mL/min. A — 107 Amended sheet 27/02/2007
0.2% triethylammonium acetate in water, B-0.2% triethylammonium acetate in ® CH;3CN. Corresponding fractions were combined, evaporated, co-evaporated with water (3 x 10 mL), dissolved in methanol (1 mL) and precipitated with ether (35 mL) to yield 117 as white solid.
Example 56
Synthesis of 7-(2°-C-methyl-B-D-ribofuranosyl)- 4- methoxylamino-pyrrolo [2.3-d]pyrimidine (118)
Nucleoside 118 was prepared from the nucleoside 141 (example 55, step 1) substituting methoxylamine for hydroxylamine.
Example 57
Synthesis of 1-(2’-C-methyl-B8-D-ribofuranosyl)- 4- hydroxylamino-pyrazolo[3.4- d]pyrimidine (120)
Step 1. Synthesis of 2.3.5-tri-O-benzoyl-2’-methyl- 1.5-dihydro-pyrazolo[3.4-d] pyrimidin-4-one (142)
Nucleoside 142 was synthesized as described in example 1 by substitution of 6-bromopurine for 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one.
Step 2. Synthesis of 2,3.5-tri-O-benzoyl-2’-methyl- 4-chloro-pyrazolo[3.4-d] pyrimidine (143)
Nucleoside 142 was dissolved in toluene, 10 equivalents of SOCI, was added and the mixture was heated at 50°C for 2 hours. The solvents were evaporated in vacuum, the residue was co-evapotated with toluene and purified by flash chromatography on silica gel (toluene-ethyl acetate, 9:1 v/v). Corresponding fractions were evaporated, dissolved in 10 mL of methanol and 5 mL NH4OH was added.
Reaction mixture was kept at room temperature overnight and evaporated. The titled nucleoside was isolated by HPLC as described in example 55, step2.
Step 3. 1-(2’-C-methyl-B-D-ribofuranosyl)- 4- hydroxylamino-pyrazolo[3.4-d] pyrimidine (120) 108 Amended sheet 27/02/2007
Nucleoside 143 was transformed to nucleoside 120 as it is described in ® example 55, step 2.
Example 58
Synthesis of 1-(2’-C-methyl-B-D-ribofuranosyl)- 4- methoxylamino-pyrazolo [3.4-d]pyrimidine (119)
Nucleoside 119 was prepared from the nucleoside 143 (example 57, step 3) substituting hydroxylamine for methoxylamine.
Example 59
Synthesis of 7-(2’-C-methyl-f-D-ribofuranosyl)- 5-chloro-4- hydroxylamino pyrrolof2.3-d]pyrimidine (123)
Nucleoside 117 (0.1 mmol) is dissolved in DMF (0.5 mL) and cooled to 0 °C.
N-chlorosuccinimide (NCS) (0.1 mmol) dissolved in DMF (0.5 mL) is then added dropwise and the reaction stirred for 30 min at 0°C and 30 min at room temperature.
The reaction is quenched with methanol (5 mL) and then concentrated. Column chromatography (SiO;) with MeOH/DCM affords 123.
Example 60
Synthesis of 7-(2°-C-methyl-B-D-ribofuranosyl)- 5-bromo-4- hydroxylamino pyrrolo[2.3-d]pyrimidine (124)
Nucleoside 124 is prepared in the same manner as for 123, substituting N- bromosuccinimide (NBS) for NCS.
Example 61
Synthesis of 7-(2°-C-methyl-B-D-ribofuranosyl)- S-methyl-4-hydroxylamino- pyrrolo[2.3-d]pyrimidine (125)
Step 1: Nucleoside 141 (1 mmol) is dissolved in DMF (5 mL) and cooled to 0°C.
NBS (1 mmol) dissolved in DMF (5 mL) is then added dropwise and the reaction stirred for 30 min at 0°C and 30 min at room temperature. The reaction is quenched with methanol (50 ml.) and then concentrated. Column chromatography (SiO,) with 109 Amended sheet 27/02/2007
® MeOH/DCM affording the 7-bromo-6-chloro-7-deazapurine riboside.
Step 2: The nucleoside from Step 1 (0.5 mmol) is dissolved in 10% aqueous dioxane (2.5 mL) and potassium carbonate (1.5 mmol) and palladium tetrakis(triphenylphosphine) are added followed by trimethylboroxine (0.5 mmol).
The reaction is refluxed for 18 hrs. then filtered through Celite and concentrated.
Column chromatography (SiO,) with MeOH/DCM affording the 7-methyl-6-chloro- 7-deazapurine riboside.
Step 3: Nucleoside 125 is synthesized as described in Example 55, step 2 using hydroxylamine.
Example 62
Synthesis of 7-(2°-C-methyl-B-D-ribofuranosyl)-5-ethyl-4- hydroxylamino- pyrrolo[2.3-d]pyrimidine (128)
Step 1: The nucleoside from Example 61, Step 1 (0.1 mmol) is dissolved in THF (1 mL) and then palladium tetrakis(triphenylphosphine) is added. To this reaction is then added diethyl zinc and the reaction heated to reflux for 6 hours. The reaction is quenched with aqueous NH4Cl and extractively worked up. Column chromatography (8107) with MeOH/DCM affording the 7-cthyl-6-chloro-7-deazapurine riboside.
Step 2: Nucleoside 128 is synthesized as described in Example 55, step 2 using hydroxylamine.
Example 63
Synthesis of 7-(2’-C-methyl-B-D-ribofuranosyl)- 5-cyano-4- hydroxylamino- pyrrolo[2.3-d]pyrimidine (126)
Step 1: To the nucleoside from Example 61, step 1 (0.5 mmol)) is dissolved in THF (5 mL) and then palladium tetrakis(triphenylphosphine) is added. To this reaction is then added zinc cyanide and the reaction heated to reflux for 6 hours. The reaction is quenched with aqueous NH4Cl and extractively worked up. Column chromatography (Si0,) with MeOH/DCM affording the 7-cyano-6-chloro-7-deazapurine riboside.
Ho Amended sheet 27/02/2007
Step 2: Nucleoside 126 is synthesized as described in Example 55, step 2 using ® hydroxylamine.
Example 64
Synthesis of 7-(2’-C-methyl-B-D-ribofuranosyl)-4- hydroxylamino-pyrrolo [2.3-d]pyrimidine S-carboxyl amide (127)
Step 1: The nucleoside from Example 63, step 1 (0.5 mmol) is dissolved in anhydrous ethanol (10 mL) and then saturated with anhydrous HCI. The reaction is stirred at room temperature overnight and then concentrated. The residue is redissolved in ethanol (5 mL) and then water (1 mL) is added and the reaction stirred for 2 hours. The solution is concentrated and purified by column chromatography (SiO) with MeOH/DCM affording the 7-carboxamide-6-chloro-7-deazapurine riboside.
Step 2: Nucleoside 127 is synthesized as described in Example 55, step 2 using hydroxylamine.
Example 65
Synthesis of 7-(2’-C-methyl-B-D-ribofuranosyl)- 5-bromo-4- methoxylamino- pyrrolo[2.3-d]pyrimidine (129)
Nucleoside 129 is synthesized from 118 as described in Example 60.
Example 66
Synthesis of 7-(2’-C-methyl-B-D-ribofuranosyl)- S-methyl-4- methoxylamino- pyrrolo[2.3-d]pyrimidine (130)
Nucleoside 130 is synthesized as described in Example 55, step 2, substituting methoxylamine for hydroxylamine.
Example 67
Synthesis of 7-(2’-C-methyl-B-D-ribofuranosyl)- 5-cyano-4- methoxylamino- pyrrolof[2.3-d]pyrimidine (131)
Hi Amended sheet 27/02/2007
® The nucleoside from example 61, step 2 is converted to 131 as described in
Example 66.
Example 69
Synthesis of 7-(2’-C-methyl-B-D-ribofuranosyl)-4- methoxylamino-pyrrolo [2.3-d]pyrimidine 5-carboxyl amide (132)
The nucleoside from example 63, step 1 is converted to 132 as described in
Example 66.
Example 70
Synthesis of 1-(2°-C-methyl-B-D-ribofuranosyl)-3-bromo- 4- hydroxylamino- pyrazolo[3.4-d]pyrimidine (133)
Nucleoside 120 is converted to 133 as described in Example 60.
Example 71
Synthesis of 1-(2’-C-methyl-B-D-ribofuranosyl)-3-methyl- 4- hydroxylamino- pyrazolo[3.4-d]pyrimidine (134)
Nucleoside 134 is synthesized from 143 using conditions described in
Example 61.
Example 72
Synthesis of 1-(2’-C-methyl-B-D-ribofuranosyl)-3-cyano- 4- hydroxylamino- pyrazolo[3.4-d]pyrimidine (135)
Nucleoside 135 is synthesized from 143 using conditions described in
Example 63.
Example 73
Synthesis of 1-(2’-C-methyl--D-ribofuranosyl) - 4- hydroxylamino-pyrazolo [3.4-d]pyrimidine- 3-carboxamide (136)
Nucleoside 136 is synthesized from 143 using conditions described in
Example 64. 112
Amended sheet 27/02/2007
® Example 74
Synthesis of 1-(2’-C-methyl-B-D-ribofuranosyl)-3-bromo- 4- methoxylamino- pyrazolo[3.4-d]pyrimidine (137)
Nucleoside 137 is synthesized from 119 using conditions described in
Example 61.
Example 75
Synthesis of 1-(2’-C-methyl-B-D-ribofuranosyl)-3-methyl- 4- methoxylamino- pyrazolo[3.4-d]pyrimidine (138)
Nucleoside 138 is synthesized from 143 using conditions described in
Example 61, substituting methoxylamine for hydroxylamine.
Example 76
Synthesis of 1-(2’-C-methyl-B-D-ribofuranosyl)-3-cyano- 4- methoxylamino- pyrazolo[3.4-d]pyrimidine (139)
Nucleoside 139 is synthesized from 143 using conditions described in
Example 63, substituting methoxylamine for hydroxylamine.
Example 77
Synthesis of 1-(2’-C-methyl-B-D-ribofuranosyl) - 4- methoxylamino-pyrazolo [3.4-d]pyrimidine- 3-carboxamide (140)
Nucleoside 140 is synthesized from 143 using conditions described in
Example 64, substituting methoxylamine for hydroxylamine.
Example 78
Synthesis of 9-(2°-C-methyl-B-D-ribofuranosyl)-6-methylthio-purine (150)
Step 1. Synthesis of 2°,3°.5°-Tri-O-benzoyl-2’-C-methyl-B-D-ribofuranosyl-6- methylthio-purine. 6-Mcthylthio-purine (1.43 g, 8.6 mmolol)) was suspended in 100 mL of dry
CH;CN, bis-trimethylsilylacetamide (BSA) was added (5 mL, 20 mmolol) and the 113
Amended sheet 27/02/2007
Claims (13)
1. A compound of Formula la R2 N—"SN ST, wo Xe R R? OHOH la wherein R and R' are independently selected from the group consisting of: hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; provided that R and R! are not both hydrogen; R? is selected from the group consisting of: cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acylamino, guanidino, amidino, thioacylamino, aryl, substituted aryl, 161 Amended sheet 27/02/2008 heteroaryl, ® substituted heteroaryl,
-NR’R* where R? and R* are joined to form, together with the nitrogen atom bond thereto, a heterocyclic, substituted heterocyclic, heteroaryl, or substituted heteroaryl, and
-NR’NR?R* where R? and R* are independently selected from the group consisting of substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R? and R* are joined to form, together with the nitrogen atom bond thereto, a heterocyclic, substituted heterocyclic, heteroaryl, or substituted heteroaryl, and R’ is selected from the group consisting of hydrogen and alkyl;
W is selected from the group consisting of:
hydrogen,
phosphate (including monophosphate, diphosphate, triphosphate or a stablilized phosphate prodrug),
phosphonate,
acyl,
alkyl,
sulfonate ester selected from the group consisting of alkyl esters, substituted alkyl esters, alkenyl esters, substituted alkenyl esters, aryl esters, substituted aryl esters, heteroaryl esters, substituted heteroaryl esters, heterocyclic esters and substituted heterocyclic esters,
a lipid,
an amino acid,
a carbohydrate,
a peptide, and cholesterol;
Y is selected from the group consisting of:
hydrogen,
halo,
hydroxy,
alkylthio, and
162 Amended sheet 27/02/2008
-NR’R* where R’ and R* are independently selected from the group ® consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R® and R* are joined to form, together with the nitrogen atom bond thereto, a heterocyclic, substituted heterocyclic, heteroaryl, or substituted heteroaryl, Z is selected from the group consisting of: hydrogen, halo, hydroxy, alkyl, azido, -NR®R* where where R? and R* are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R’ and R* are joined to form, together with the nitrogen atom bond thereto, a heterocyclic, substituted heterocyclic, heteroaryl, or substituted heteroaryl, and NR’NR’R* where R? and R* are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R’ and R* are joined to form, together with the nitrogen atom bond thereto, a heterocyclic, substituted heterocyclic, heteroaryl, or substituted heteroaryl, and : R’ is selected from the group consisting of hydrogen and alkyl; and pharmaceutically acceptable salts thereof.
2. A compound according to Claim 1 wherein R is hydrogen and R'is methyl.
3. A compound according to Claim 1 wherein W is hydrogen.
4. A compound according to Claim 1 wherein Z is hydrogen. 163 Amended sheet 27/02/2008
® 5. A compound according to Claim 1 wherein Y is hydrogen or NH.
6. A compound according to Claim 1 wherein R'is methyl; R, W, and Z are hydrogen; and Y is hydrogen or NH,.
7. A compound of Claim 1 selected from the group consisting of: 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(thiophen-3-yl)-purine (1); : 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(thiophen-2-yl)-2-aminopurine (2), 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(pyrrol-3-yl)-purine (3); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-phenyl-2-aminopurine (4); 9-(2’-C-methyl-p-D-ribofuranosyl)-6-(3-cyanophenyl)-purine (5); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(pyridin-3-yl)-purine (6); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(benzo[b]thiophen-3-yl)-2-aminopurine (7); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(1H-indol-5-yl)-purine (8); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(naphthalen-2-yl)-purine (9); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(dibenzofuran-4-yl)-2-aminopurine (10); 9-(2’-C-methyl-p-D-ribofuranosyl)-6-(thianthren-1-yl)-purine (11); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-cyclopropyl-2-aminopurine (13); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(ethynyl)-purine (14); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-[2-aminocarbonyl-(pyrrolidine-1-yl)]- purine (25); 9-(2’-C-methyl-B-D-ribofuranosyl)- 6-(1,3,4,9-tetrahydro-beta-carbolin-2- yD)purine (33); 9-(2’-C-methyl-B-D-ribofuranosyl)- N° —{[(3H-indol-3-yl)-acetic acid]- hydrazide} adenine (53); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(piperidin-1-yl)purine (57); 9-(2’-C-trifluoromethyl-B-D-ribofuranosyl!)-6-[2-aminocarbonyl-(pyrrolidine- 1-yl)]-purine (64); 9-(2’-C-ethenyl-B-D-ribofuranosyl)-6—[2-aminocarbonyl-(pyrrolidine-1-yl)]- purine (70); 9-(2’-C-ethynyl-p-D-ribofuranosyl)-6-[2-aminocarbonyl-(pyrrolidine-1-yl)}- purine (76); 164 Amended sheet 27/02/2008
9-(2’-C-methyl-B-D-ribofuranosyl)- 6-(azetidin-1-yl)purine (107); ® 9-(2’-C-methyl-B-D-ribofuranosyl)- 6-(pyrrolidin-1-yl)purine (108); 9-(2’-C-methyl-B-D-ribofuranosyl)- 6-(1,2,3,4-tetrahydropyridin-1-yl)purine (113); 9-(2’-C-methyl- B -D-ribofuranosyl)-6-(1,2,3,4-tetrahydroisoquinolin-2- yl)purine (114); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(6-fluoro-1,3,4,9-tetrahydro-fB-carbolin- 2-yl)purine (163); 9-(2°-C-methyl-B-D-ribofuranosyl)-6-(3,6-dihydro-2H-pyridin-1-yl)purine (164); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-phenyl-purine (170); 9-(2’-C-methyl-B-D-ribofuranosyl)-6-(tetramethylguanidino)purine (178); 9-(2’-C-methyl-B-D-ribofuranosyl)purine-6-carboxamide (208); and 9-(2’-C-methyl-B-D-ribofuranosyl)-9H-purine-6-carbothioic acid amide (209).
8. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound or mixture of any one of the compounds of Claims 1 to 7.
9. Use of a composition of Claim 8 for the treatment of hepatitis C virus in a mammal diagnosed with hepatitis C virus, or at risk of developing hepatitis C virus.
10. Use of any one of the compounds of any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of hepatitis C virus in a mammal diagnosed with hepatitis C virus, or at risk of developing hepatitis C virus.
11. A process of preparing 2’C and/or 3’C branched ribonucleosides of Formula Ia as defined in Claim 1, comprising coupling an optionally protected sugar to a purine base,
12. A process of preparing 2’C and/or 3’C branched ribonucleosides of Formula la as defined in Claim 1, comprising coupling an organometallic carbon nucleophile with a ketone, said ketone having been produced by oxidizing an optionally protected nucleoside. 165 Amended sheet 27/02/2008
13. A compound of Formula Ia as defined in claim 1, uses thereof, pharmaceutical ® composition thereof, methods and uses involving said pharmaceutical compositions and/or processes of preparing said compounds substantially as herein described with reference to the examples herein. 166 Amended sheet 27/02/2008
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37862402P | 2002-05-06 | 2002-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200408588B true ZA200408588B (en) | 2007-03-28 |
Family
ID=40513337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200408588A ZA200408588B (en) | 2002-05-06 | 2003-05-06 | Nucleoside derivatives for treating hepatitis C virus infection |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200408588B (en) |
-
2003
- 2003-05-06 ZA ZA200408588A patent/ZA200408588B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040063658A1 (en) | Nucleoside derivatives for treating hepatitis C virus infection | |
US7629320B2 (en) | Nucleoside derivatives for treating hepatitis C virus infection | |
US7157434B2 (en) | Nucleoside compounds for treating viral infections | |
US7125855B2 (en) | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | |
US20040110717A1 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | |
EP1476169A1 (en) | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | |
WO2002018404A2 (en) | Nucleoside derivatives for the treatment of hepatitis c | |
EP1853618A1 (en) | Tricyclic-nucleoside compounds for treating viral infections | |
WO2006116557A1 (en) | Nucleoside compounds for treating viral infections | |
AU2007338899A1 (en) | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection | |
US20070167383A1 (en) | Nucleoside compounds for treating viral infections | |
US7414031B2 (en) | 5-nitro-nucleoside compounds for treating viral infections | |
ZA200408588B (en) | Nucleoside derivatives for treating hepatitis C virus infection | |
TW200423945A (en) | Nucleoside derivatives for treating hepatitis c virus infection |